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1 INTRODUCTION  
 
Understanding the distribution of drugs into the brain is important for both drugs with 
targets in the central nervous system (CNS) and for non-CNS drugs. For CNS drugs, 
suitable permeability is needed for the drug to reach its target and to achieve the desired 
pharmacological effect. With drugs targeted to act in other tissues, penetration into the 
brain can result in unwanted and potentially toxic side-effects. For this reason there is a 
lot of interest in finding simple and effective low-cost, high throughput methods to 
evaluate the brain disposition of drug candidates as early as possible in drug discovery. 
Currently,  there  is  no  method that  meets  all  these  requirements,  but  many useful  tools  
for the characterization of drug behavior at the blood-brain barrier (BBB) have been 
developed. 
 
Previously, lipophilicity of the drug was considered to be the main determinant of brain 
penetration, but empiric observations showed deviation from this. Simple physico-
chemical properties and octanol/water partition coefficients do not correctly predict 
partitioning for all compounds. With increasing knowledge of active transport systems, 
it has been widely accepted that the influx and efflux transporters are a major 
determinant of brain distribution for many compounds and that their effects should be 
considered in drug development. 
 
The array of available techniques to study drug distribution into the brain ranges from 
simple in vitro cell based assays to microdialysis studies in animals. In silico methods 
are being developed, as the aim is to make predictions of possible consequences of 
efflux in man as early as possible in drug development. A range of studies is needed 
throughout development from quick recognition of substrates to more complicated 
studies of mechanisms and significance of active transport at the blood-brain barrier. 
 
The aim of this literature review is to give an overview of the different strategies 
applied to study blood-brain barrier permeability and the effects of active transport 
systems on the brain distribution of drugs. Focus will be on p-glycoprotein (MDR1) 
which has received the most interest in the pharmaceutical industry. Although the 
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methods are primarily described here for studies of p-glycoprotein, the principles can be 
applied to studying other active transport proteins. In addition, the consequences and 
clinical significance of p-glycoprotein mediated transport will be considered with regard 
to inter-individual variability (i.e. polymorphisms) and possible drug-drug interactions. 
 
 
2 CHARACTERISTICS OF THE BLOOD-BRAIN BARRIER 
 
2.1 Structure of the Blood-Brain Barrier 
 
The blood-brain barrier (BBB) consists of brain capillary endothelial cells which are 
surrounded by astrocytic perivascular endfeet and pericytes (Abbott et al. 2006) (Figure 
1). With a surface area of 12-20 m2/ 1.5 kg brain, it is an important barrier separating 
the brain from the systemic circulation (Abbott et al. 2008). The brain is well perfused 
by blood and receives around 15 % of the minute volume, roughly 700 ml/min of blood 
in an adult human, with flow differing between discrete regions (Davies and Morris 
1993; Zhao and Pollack 2009). The network of microvessels in the brain is dense and 
the distance from the brain microvessels to the surrounding neurons is short, roughly 8-
20 ?m (Abbott et al. 2006).  
 
Figure 1. The blood-brain barrier (adapted from Abbott et al. 2008).  
 
In addition to the BBB, the brain has another barrier which regulates movement of 
molecules, the blood-cerebrospinal fluid barrier (BCSFB) (de Lange 2004). The BCSFB 
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is composed of the choroid plexus, the arachnoid membrane and periventricular organs. 
The surface area of the BCSFB has previously been reported to be over three orders of 
magnitude smaller than the BBB, but more recently, taking into account the microvilli 
in the epithelial cells, it is thought that the difference may only be 2-fold (Westerhout et 
al. 2011). However, the distance to surrounding neurons can be as much as centimeters 
from  the  CSF  and  less  is  known  about  the  significance  of  the  BCSFB  (Abbot  et  al.  
2006).  For  these  reasons,  it  is  the  BBB that  is  often  thought  to  be  the  most  important  
barrier limiting the transport of compounds into the brain, although the BCSFB is 
receiving increasing interest (Kusuhara and Sugiyama 2001; de Lange 2004; Abbott et 
al. 2006).   
 
The  BBB  is  distinguished  from  other  capillaries  by  low  levels  of  endocytosis  and  
paracellular diffusion (Abbott et al. 2006). The endothelial cells are joined together by 
tight junctions and adherence junctions, which results in an extremely impermeable 
barrier with transendothelial resistance (TEER) of more than 1000 ?/cm2. Tight 
junctions are formed by special proteins of which most important are occludins and 
claudins alongside zonula occludens proteins 1 and 2. In addition to decreasing 
permeability, the tight junctions also help to make up the polarized form of the BBB.  
 
The blood-brain barrier regulates the movement of endogenous substances that are vital 
for normal physiological functions as well as serving as a protective barrier to shield the 
brain against harmful xenobiotics (Abbott et al. 2006). Due to the limited paracellular 
diffusion of compounds across the BBB, only small, lipophilic molecules are able to 
permeate by passive diffusion, which means that for other molecules, specialized 
transport proteins are necessary for transport. These active transporters may also hinder 
the entry of compounds into the brain depending on the direction of transport.  
 
In addition to transport proteins, the existence of metabolizing enzymes in both brain 
parenchyma and the blood-brain barrier has been noted (Dutheil et al. 2010). The two 
CYP450 enzymes that have been detected in brain microvessels are CYP1B1 and 
CYP2U1, of which 1B1 is by far the most abundant (80%) (Dauchy et al. 2008). So far, 
no important drug substrates have been identified for these enzymes, and so their role in 
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the brain distribution of clinical drugs is unclear (Dutheil et al. 2010). They could, 
however, have a role in metabolizing endogenous substances such as arachidonic acid, 
which is a substrate of both enzymes. At the moment it seems that for drugs at the BBB, 
metabolizing  enzymes  have  a  smaller  role  than  transporters,  but  further  studies  are  
needed to conclude this.  
 
2.2 Transport Proteins 
 
A  range  of  energy,  amino  acid,  neurotransmitter  and  nucleoside  transport  systems  are  
needed to maintain homeostasis in the brain (Ohtsuki and Terasaki 2007). The presence 
of a variety of different transporters of both the ABC (ATP binding cassette) and SLC 
(solute carrier) families in brain microvessel endothelial cells has been studied (Cooray 
et al. 2002; Dauchy et al. 2008; Shawahna et al. 2011; Uchida et al. 2011a). P-
glycoprotein (ABCB1) and the breast cancer resistance protein BCRP (ABCG2) have 
been detected in human brain microvessels as the major transporters alongside 
substantially lower levels of MRP (ABCC) transporters 1, 4 and 5 (Dauchy et al. 2008; 
Shawahna et al. 2011; Uchida et al. 2011a).  
 
BCRP is the most highly expressed transporter at the human BBB, where it acts as an 
efflux on the luminal membrane (Cooray et al. 2002; Cisternino et al. 2004a, Dauchy et 
al. 2008; Uchida et al. 2011a). Substrates of BCRP include chemotherapeutics 
(mitoxantrone, topotecan), antivirals, HMG-CoA reductase inhibitors, antibiotics and 
calcium channel blockers among others, some of which are shared by p-glycoprotein 
(Litman et al. 2000; Cisternino et al. 2004a, Robey et al. 2009). Despite having a range 
of substrates in different therapeutic classes, for the time being, the significance of 
BCRP on the brain distribution of drugs remains debatable and demands further studies 
(Cisternino et al. 2004a; Zhao et al. 2009a). P-glycoprotein, the most extensively 
characterized transporter expressed at the BBB will be discussed in more detail in 
section 2.3. 
 
Several SLC transporters including EAAT1 (excitatory amino acid transporter 1) and 
GLUT1 (glucose transporter 1) alongside low levels of LAT1 (L-type amino acid 
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transporter 1) are also expressed at the BBB (Uchida et al. 2011a). The protein 
expression of other transporters such as peptide (PEPT), organic anion (OATP and 
OAT) and organic cation (OCT) transporters remains to be elucidated at the human 
BBB, though some of these (e.g. oatp2) have been detected in mice (Kamiie et al. 
2008).  Expression of Oatp2 and its  human homolog OATP-A (OATP1A2) at  the BBB 
has also been shown by Western blot in rats and humans, respectively (Gao et al. 1999; 
Gao et al. 2000). The assumed localization of the detected proteins is shown in Figure 2. 
 
Figure 2. Presumed localization of transporters and direction of transport at the blood-
brain barrier (Ohtsuki and Terasaki 2007). “BMECs” refers to the brain microvessel 
endothelial cells and “P-gp” to p-glycoprotein. 
 
In  addition  to  structural  differences,  the  blood-brain  and  blood-CSF  barrier  also  show  
differing transporter expression (de Lange 2004, Kusuhara and Sugiyama 2001). For 
example MRP1 is clearly present in the choroid plexus, but its expression at the BBB is 
still under question, whereas unlike at the BBB, only low expression level of p-
glycoprotein is detected at the BCSFB (Gazzin et al. 2008). At the BCSFB, MRP1 and 
p-glycoprotein also seem to have opposing transport directions to that at the BBB (de 
Lange 2004). Of the solute carrier transporter family at least oatp3 and oat3 have been 
identified at the BCSFB in mice.   
 
Transporter protein expression level and their role at the blood-brain barrier remains 
unclear for many of the transporters, especially MRPs, but should become more clear 
with the development of more sensitive quantitative analysis methods for proteins. 
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These proteins have been detected in mRNA level, but Western blot results have been 
inconclusive (Cooray et al. 2002; Dauchy et al. 2008). The inability to detect these 
proteins does not necessarily mean lack of existence, but could be due to the limitations 
of the analysis methods. Because, due to ethical reasons, human brain tissue used in 
most studies is from diseased subjects, there is always the question of whether these 
tissue samples represent protein levels in healthy human tissue. However, Dauchy et al. 
(2008) showed similar mRNA in samples from epilepsy patients and “commercial” 
brain cortex RNA. 
 
2.3 P-Glycoprotein  
 
P-glycoprotein (MDR1), the product of the ABCB1 gene, is a 170 kDa transport protein 
that is a member of the ABC family of transporters. It was initially found in tumor cells 
resistant to various different chemotherapeutics and was determined to be the reason for 
this multidrug resistance (MDR). In addition to tumors, p-glycoprotein is present in 
healthy tissue in various organs throughout the body where it is thought to serve a 
protective role against xenobiotics (Thiebaut et al. 1987; Cordon-Cardo et al. 1989; 
Cordon-Cardo et al. 1990; Schinkel et al. 1994). P-glycoprotein is mainly expressed in 
the intestine, liver, kidney, blood-brain barrier, adrenal tissue, testes, placenta and lungs. 
The polarized expression and localization of p-glycoprotein in these excretory organs, 
for example the biliary ducts of the liver, further highlight its role in removing 
substances from the body (Thiebaut et al. 1987). 
 
Recently it has been shown that at the human BBB p-glycoprotein is the second most 
prominent transporter (Dauchy et al. 2008; Shawahna et al. 2011; Uchida et al. 2011a). 
In the brain microvessel endothelial cells (BMECs), p-glycoprotein is situated at the 
luminal membrane, where it enhances efflux of drugs from the brain back into the blood 
(Cordon-Cardo  et  al.  1990;  Bendayan  et  al.  2006).  In  addition  to  this  Bendayan  et  al.  
(2006) also suggested the abluminal localization.  P-glycoprotein has a large range of 
structurally unrelated substrates including chemotherapeutic agents such as vinca 
alkaloids (vinblastine, vincristine), opioids (morphine, loperamide), HIV-protease 
inhibitors (nelfinavir), antihistamines (fexofenadine) and antiarrythmics (quinidine, 
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digoxin) in addition to some drugs used treat CNS disorders, such as antidepressants 
(citalopram, fluvoxamine, venlafaxine) (Schinkel et al. 1996; Kim et al. 1998, Uhr et al. 
2008; Doran et al. 2005, Obradovic et al. 2007). Also some drugs, like cyclosporine A, 
have been identified as inhibitors and more potent derivatives have been developed, in 
hopes of overcoming multidrug resistance (Yang et al. 2008).   
 
The ability of p-glycoprotein to transport such a large range of different molecules, 
points to the existence of multiple binding sites, which is supported by results from 
probe interaction studies (Martin et al. 2000). At least four different interaction sites 
have been found, some of which seem to be important for actual transport and others for 
the regulation of function. The mechanism of action of p-glycoprotein has also been of 
great  interest  and  it  is  currently  thought  to  act  in  two  different  ways,  by  efflux  
enhancement from the intracellular fluid and by influx hindrance (Stein et al. 1994; 
Sharom 1997). In the latter mechanism drugs partitioning into the lipid bilayer interact 
directly in the membrane with p-glycoprotein and are effluxed before entering the 
intracellular fluid.  This can result in flip-flop or futile cycling of lipophilic drugs, 
which partition back into the lipid layer quickly after extrusion only to be effluxed 
again. 
 
P-glycoprotein has received a lot of interest due to its large substrate specificity and to 
the  fact  that  it  may affect  the  distribution  and  elimination  of  drugs  in  many organs.  It  
has been shown in knockout animals, that the brain distribution of substrates is 
especially susceptible to the function of p-glycoprotein (Schinkel et al. 1996; Kim et al. 
1998; Dagenais et al. 2001). With this in mind, identifying the interaction of drugs with 
p-glycoprotein has become a common practice in drug development to avoid possible 
interactions, optimize brain permeation and circumvent drug resistance.   
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3 IN VITRO METHODS 
 
3.1 Parallel Artificial Membrane Permeability Assay (PAMPA) 
 
The parallel artificial membrane permeability assay (PAMPA) is an in vitro method 
used to evaluate passive permeability properties of compounds (Kansky et al. 1998). 
Because passive transcellular diffusion is an important factor in the disposition of drugs 
into the brain, there has been interest in using PAMPA for the early prediction of brain 
permeability (Di et al. 2003). PAMPA is based on compound permeating on a 96-well 
plate through a phospholipid impregnated filter that mimics a lipid barrier. Although it 
was originally described by Kansky et al. (1998) as an intestinal absorption model, the 
membrane can be modified to resemble the blood-brain barrier composition by using, 
for example, porcine polar brain lipid (PBL) as the phospholipid component (PAMPA-
BBB) (Di et al. 2003).  
 
The PAMPA-BBB has been used both to predict passive BBB permeability and to 
classify drugs as CNS positive or negative (Di et al. 2003; Di et al. 2008, Mensch et al. 
2010a). The black lipid membrane (PAMPA-BLM) has also proved successful as a 
preliminary blood-brain barrier screen (Mensch et al. 2010a). As well as being able to 
rank compounds into groups of low, moderate and high permeability, the PAMPA 
method (on its own or in combo with Abraham descriptors) also seems to correlate well 
with in situ brain perfusion results from high concentration studies or equivalent 
conditions (i.e. knockout or inhibition studies) where efflux is most likely saturated (Di 
et al. 2008, Dagenais et al. 2009).    
 
The reason why PAMPA is useful is that it is a measure of transcellular permeability, 
which is the primary route of passive transport at the BBB (Kansky et al. 1998). 
Therefore it mimics passive diffusion at the BBB better than the leaky in vitro cell 
models,  where  the  role  of  paracellular  transport  is  emphasized.  It  is  also  a  high-
throughput method that does not require days of preparation and throughput is only 
limited by availability of suitable analysis methods (Kansky et al. 1998). The incubation 
time can be shortened with only a slight decrease in predictability and the method 
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allows a cassette approach of testing multiple compounds at once (Carrara et al. 2007). 
The drawback is that although PAMPA is a simple experimental method, several 
calculation and experimental steps, for example determinations in several pH 
conditions, will need to be undertaken to be able to fully account for factors such as the 
aqueous boundary layer (ABL) and charge effects, which can influence results 
(Dagenais et al. 2009). At least in the in combo application PAMPA also seemed to 
have lower success in predicting in vivo BBB permeability (LogPS) for neutral 
compounds and zwitterions, compared with acids and bases.    
 
The results of PAMPA could be incorporated into predictive models, though this 
seemed to have limited effect on prediction outcomes in a study by Mensch et al. 
(2010b). Even if permeability measured with PAMPA is unlikely to correctly represent 
actively transported drugs, it can be used early on in development to prioritize drug 
candidates and also used in parallel with more time consuming cell experiments that do 
include active processes (Dagenais et al. 2009).  
 
3.2 Cell Models of the Blood-Brain Barrier 
 
Many different in vitro models have been developed for studies of drug permeation at 
the blood-brain barrier (Abbott et al. 2008). The development of a stable, reproducible, 
easily cultured model that maintains the morphological and functional properties of the 
BBB has proven difficult (Gumbleton and Audus 2001). Efforts have been made to 
derive models from brain microvessel endothelial cells of different species such as rats, 
mice, pigs and cows (Table 1). Primary cultures of brain endothelial microvessel cells 
show the least dedifferentiation, but their use has problems of inter-batch variability and 
availability in some species (Gumbleton and Audus 2001). Different methods of 
inducing the blood-brain barrier phenotype have been studied, especially co-cultures 
with  astrocytes  and  the  predisposing  of  cells  to  shear-resistance  of  flow.  Although  
ultimately, the manipulation of cells with different culture conditions could be useful, it 
remains a problem because the processes governing differentiation are not yet 
completely understood.   
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Table 1. A summary of the properties of developed in vitro models of the blood-brain 
barrier and surrogate cell lines used to study p-glycoprotein effects 
In vitro 
Model 
Source TEER 
Value 
??*cm2) 
Advantages/ Disadvantages 
Primary /low passage cultures: 
BBMEC a Bovine 160–200 + Availability from slaughterhouses, phenotype 
close to BBB 
- Phenotype is lost over time, need for continual 
isolation, variability between batches, BSE 
PBMEC b Porcine 600–800a 
300–550b 
+ Higher TEER value and shorter time to confluence 
than BBMEC, availability from slaughterhouses, 
phenotype close to BBB,  isolated cells can be frozen 
 - Variability, phenotype is lost over time  
MBMEC c Murine < 200 + Relevance to in vivo models in drug industry 
- Low yield of cells from one animal, low TEER 
value 
Immortalized cell lines 
b.End3 d 
b.End5 e 
Murine ? 130 + Commercially available, possibility of use in 
transport studies because expresses typical 
transporters, relevance to in vivo studies in mice 
-  Not applicable to permeability studies due to low 
TEER, weak distinction between high and low 
permeability compounds 
hCMEC/D3 f Human < 40 + Human origin, similar protein expression to 
isolated brain microvessels 
- Transporter expression moderate, relevant TEER 
not yet achieved 
Surrogate, immortalized cell lines of non-brain origin 
MDR1-
MDCKII a 
Canine 
kidney 
100–200 
1800–2000 g 
+ Relatively selective for p-gp, short growth time 
- Different morphology and lipid composition, 
suboptimal TEER, lacks other systems than p-gp, p-
gp over expression, relevance questionable 
Caco-2h Human 
colon 
600–1000  
(N.B. unit 
?) 
+ Readily available, high TEER well characterized 
- Different morphology, expression of non-brain 
systems, overlap between transporter substrates, 
relevance questionable  
a) Gumbleton and Audus 2001 b) Zhang et al. 2006 c) Shayan et al. 2011  d) Omidi et al. 2003  
e) Yang et al. 2007 f) Weksler et al. 2005; Poller et al. 2008;  Dauchy et al. 2009  
g) Summerfield et al. 2007 h) Garberg et al. 2005 
 
The main problem with the immortalized cell lines described in literature is the loss of 
cell layer tightness, a problem which also exists with the primary cultures (Gumbleton 
and Audus 2001). Due to this increased paracellular permeability there is currently no 
BBB model that can reliably be used for permeability assays of drug. Instead the cell 
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lines can be used to study active uptake of drugs, because they express the typical BBB 
transporters. The cells are however not applicable to studies of efflux.  
 
A promising immortalized cell line of human origin, hCMEC/D3, has recently been 
characterized (Weksler et al. 2005; Poller et al. 2008; Dauchy et al. 2009). The 
expression of transporters and CYP enzymes in the cell line is qualitatively similar to 
that in freshly isolated brain microvessels, though slightly lower and missing CYP1B1 
expression (Dauchy et al. 2009). Despite a leakier phenotype than the in vivo BBB, the 
hCMEC/D3 cell line has been reported to be able to discriminate markers of low and 
high passive permeability and correlate well (R = 0.938) with permeability measured 
with in situ brain perfusion for a limited set of compounds (Weksler et al. 2005; Poller 
et al. 2008). However, the magnitude of permeability is far from the in vivo situation as 
the reported permeability range in the cell line was roughly 0.5 – 5.5 *10-3 cm/s (Poller 
et al. 2008). Regarding other properties such as protein expression, the hCMEC/D3 cell 
line is one of the more promising tools. 
 
Due to the problems with in vitro brain microvessel cultures, surrogate immortalized 
cell lines have been used in studies of active transport (Adachi et al. 2001; Yamazaki et 
al. 2001; Hakkarainen et al. 2010). Popular non-brain derived cell lines include the 
MDR1 transfected MDCKII (Madin-Darby canine kidney) or LLC-PK1 (porcine 
kidney) cell lines. Colon carcinoma derived Caco-2 cells that naturally express p-
glycoprotein have been used in permeability and efflux studies, though more with 
respect to predicting p-glycoprotein effects on intestinal absorption. Although these cell 
lines lack many properties of the blood-brain barrier, they can be used for screening and 
studying interactions of drugs with transporters. In a study with a wide range of 
different BBB in vitro models, the MDR1-MDCKII cell line was concluded to most 
efficiently separate compounds undergoing significant efflux from mainly passively 
distributing compounds (Garberg et al. 2005). 
 
With surrogate cell lines such as MDCK, the transporter to be transfected can be 
chosen. This protein should always be chosen to coincide with the species used in 
comparative in vivo data due to the possibility of interspecies variability. Feng et al. 
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(2008) showed fairly good correlation between mouse and human p-glycoprotein efflux 
in a large set of CNS compounds (n=32) and also for 3300 Pfizer compounds (R2 = 
0.92), while in a smaller set (n=12) Takeuchi et al. (2006) reported a poor correlation. In 
other studies kinetic parameters (Vmax and Km) of some compounds showed interspecies 
differences (Katoh et al. 2006). 
 
The properties of cell lines are diverse in relation to permeability, expressed proteins 
and the level of expression (Table 1). Permeability values for the same compound can 
differ by as much as one order of magnitude depending on the cell line (Hakkarainen et 
al. 2010) (Table 2). There are also problems with in vivo extrapolation as in vitro 
measured permeabilities in brain derived cell models can be as much as 150 times 
greater than those measured in situ (Pardridge et al. 1990). Despite differences in 
permeability, the BBMECs, Caco-2 and MDCKII-MDR1 cell lines are able to 
categorize compounds similarly into three groups of low, intermediate and high 
permeability (Hakkarainen et al. 2010). With regard to active transport, the different 
expression levels of transporters can complicate comparability. 
 
Table 2. Permeability values of sucrose (a paracellular permeability marker) and 
midazolam (a high permeability compound) in various cell lines. 
 Caco-2 a MDR1-MDCKII a BBMEC a hCMEC/D3 b  
Sucrose Papp x 106 cm/s 2.4 0.7 34.9 26.7 
Midazolam Papp x 106 cm/s 39.3 42.0 298.4 85.5 
a) Hakkarainen et al. 2001 b) Poller et al. 2008 
 
The role of passive permeability should not be overlooked even when studying active 
processes as permeation is the sum of both passive and active mechanisms (Sugano et 
al. 2010). In vivo predictions from in vitro results are difficult since no in vitro 
conditions are currently able to imitate both. In addition to affecting the significance of 
active transport, the passive permeability of a drug also affects the ability of a drug to 
permeate the blood-brain barrier and should therefore be evaluated (Wang et al 2005). 
Highly effluxed compounds can still be useful CNS drugs if they have a high enough 
passive permeability. Due to the limitations of cell lines and complex relationship 
between passive and active transport, combinations of study methods are needed to fully 
characterize transport (Feng et al. 2008). Even so, present in vitro methods are perhaps 
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more suited to ranking compounds in order of permeability than determining actual rate 
of transport.  
 
3.3 Transcellular Transport Studies in Cell Monolayers 
 
A common way of measuring transport across membranes and studying the effect of 
active processes is the use of cell monolayers like the ones described in section 3.2. To 
determine the effects of active transporters, transcellular transport assays are performed 
in both apical to basolateral and basolateral to apical directions (Figure 3). If only 
passive diffusion affects transport, the flux is assumed to be identical in both directions, 
but the participation of transporters results in a polarized or asymmetrical transport in 
either direction. With p-glycoprotein, efflux at the apical membrane results in an 
increased flux in the basolateral to apical direction.   
 
Figure 3.  Principles of the transcellular transport  experiment in cell  monolayers.  ER is 
the efflux ratio. PappA-B and PappB-A are the apparent permeabilities of compound from the 
apical to the basolateral and basolateral to apical chamber, respectively. 
 
When active transport is studied using monolayers, the parameter used to depict active 
processes is usually the efflux ratio (ER) which is the basolateral to apical permeability 
(PappB-A)  divided  by  the  permeability  in  the  other  direction  (PappA-B) (Figure 3). The 
apparent permeability is calculated according to equation 1: 
???? = ???? × ?????    (1) 
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where dQ/dt is the cumulative amount of drug in the receiver chamber versus time, S is 
the surface area of the monolayer and C0 is the initial concentration in the donor 
chamber.  
 
The efflux ratio gives an idea of directional transport although it does not elucidate the 
separate underlying effects on the inward and outward fluxes (Troutman and Thakker 
2003). It is not unusual that some directional transport is present even in the parent cell 
line  owing  to  the  presence  of  transporters  endogenous  to  the  cells.  Due  to  this,  some  
research groups standardize results for the basal asymmetry, which can improve the in 
vitro - in vivo correlation of the results (Adachi et al. 2001, Feng et al. 2008). The utility 
of this can however be questioned, as expression of endogenous transporters can change 
with transfection, obscuring relationships (Kuteykin-Terplyakov et al. 2010).  
 
The interpretation of in vitro ER data can be complicated because ER values can vary 
between cell lines, depending on the expression levels of the transporter and the passive 
(paracellular) permeability of the cell line (Adachi et al. 2001). Suggested values for the 
cutoff for in vitro values ER vary around 1.5 and 2, but there is no clear consensus on 
which value would mean a significant p-glycoprotein effect in vivo (Polli et al. 2001; 
Feng et al. 2008). The cutoff could also be specific to the cell system, due to the above 
factors.  To  overcome  the  problem  of  differing  passive  diffusion,  a  variation  of  the  
common method, called the concentration equilibrium transport assay, uses equal 
concentrations  of  drug  in  both  chambers  in  the  monolayer  assay  (Luna-Tortos  et  al.  
2008). In this setting the influence of passive permeability is minimal. Other 
experimental factors, such as stirring conditions, could however also affect the results of 
the monolayer transport studies (Hakkarainen et al. 2010).  
 
The transcellular transport assay may not be able to distinguish p-glycoprotein 
substrates that have very low or very high passive permeability (Lentz et al. 2000). Low 
passive permeability can result in little effect of efflux owing to the low concentrations 
of the drug available at the binding site whereas high permeability can mask efflux. 
Polli et al. (2001) are in favor of the transcellular transport assay, because it is useful in 
distinguishing p-glycoprotein effects for compounds with intermediate permeability    
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(< 300 nm/s). This is rationalized as even though it may mean more false negatives for 
high permeability compounds, for these compounds the in vivo role of p-glycoprotein is 
likely to be insignificant. 
 
The benefit of the transcellular transport assay is that it measures the movement of drug 
from one chamber to the other, which mechanistically resembles the events at the 
blood-brain barrier better than assays that measure secondary outcomes of drug-
transporter interaction like the calcein-AM and ATPase activity assays (see 3.4 Other 
Assays) (Feng et al. 2008). It can also be used to determine the Michaelis-Menten 
parameters of active transport, when studies are carried out over a concentration range 
and data fitted (Bachmeier et al. 2006; Shirasaka et al. 2008a). However, the robustness 
and relevance of these kinetic studies is disputed as for example concentrations at the 
binding site cannot be measured for efflux proteins. In addition to kinetic studies, 
monolayers can also be used to study interactions between p-glycoprotein substrates 
(Rautio et al. 2006). 
 
With a relevant cell line that truly, qualitatively and quantitatively, mimics the blood-
brain barrier, the permeability of compounds in both directions could be easily 
determined in one assay. Unlike the currently used cell lines, the relationships between 
active and passive processes would be much more apparent in such a model. Until the 
problems of the brain derived cell lines are overcome, the transfected cell lines will 
continue to be used as a surrogate first step in characterizing transport. All in all, fairly 
good correlation has been achieved between p-glycoprotein ER measured in monolayers 
and in vivo ER defined with knockout and wild-type mice (Adachi et al. 2001; 
Yamazaki et al. 2001; Chen et al. 2003; Feng et al. 2008).  
 
3.4  Other Assays 
 
In addition to the transcellular transport assay, there are at least two other well 
characterized in vitro cell based methods to determine interactions of drugs with p-
glycoprotein. These are the calcein-AM assay and the ATPase activity assay (Polli et 
al.2001; Schwab et al. 2003; Feng et al. 2008). Unlike the transcellular transport assay 
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these do not measure the rate of transport, but instead detect secondary measures of 
interaction of drugs with transport proteins.  
 
The calcein-AM assay is based on calcein-acetoxymethylester (calcein-AM), a non-
fluorescent p-glycoprotein substrate, being hydrolyzed inside the cell to calcein (Bauer 
et al. 2003; Bubik et al. 2006) (Figure 4). Calcein is a fluorescent molecule that is 
trapped inside the cell, due to its hydrophilic nature. It can be detected easily by 
fluorometric analysis and intracellular fluorescence is evaluated as a measure of p-
glycoprotein interaction. Increase in fluorescence suggests inhibition of p-glycoprotein. 
Cells such as porcine brain capillary endothelial cells (PBCECs) are used, but others are 
possible as long as they express p-glycoprotein at an appropriate level. Calcein-AM and 
calcein may interact with MRP transporters, but the effect is negligible according to 
Bauer et al. (2003) although there may be differences depending on the expression of 
MRPs in the cells used. Depending on the cells and compounds tested, other 
transporters could also complicate interpretation. 
 
Figure 4. Schematic representation of the calcein-AM assay. Interaction of drugs with 
p-glycoprotein (P-gp) is measured as an increase in fluorescence, as more calcein-AM 
will remain in the cell and be metabolized due to transporter inhibition (Modified from 
Bauer et al. 2003).  
 
The other assay, ATPase activity assay, utilizes the ATP dependency of active transport, 
as it measures the amount of liberated inorganic phosphate when test compounds are 
incubated with Sf9 insect cell membranes expressing p-glycoprotein (Sarkadi et al. 
1992; Boulton et al. 2002). In the assay, drugs that are transported by p-glycoprotein 
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should  show  an  increase  in  the  activity  of  the  protein  and  thus  in  the  amount  of  free  
inorganic phosphate, which can be measured with photometric assays (Shirasaka et al. 
2006). As well as categorizing compounds as substrates, the affinity of drug to p-
glycoprotein (Km)  and  the  maximal  amount  of  inorganic  phosphate  release  (Vmax) can 
be calculated. The calcein-AM assay can also be used to characterize the nature of p-
glycoprotein inhibition (Bauer et al. 2003).   
 
The advantage of these methods is the ease of detection and the possibility for high 
throughput analysis.  An improved method of the calcein-AM assay proposed by Bubik 
et al. (2006) uses isolated PBCECs in suspension rather than monolayers, thus avoiding 
incubation of cells and need for aseptic conditions. Even with this modification, the 
assay showed the ability to categorize compounds into substrates and non-substrates. 
Also, the use of brain endothelial cells in this assay improves relevance to blood-brain 
barrier processes. The ATPase activity assay however, uses insect cell membranes 
which may have different properties than mammalian cells (Feng et al. 2008). 
   
There is some inconsistency between results from the ATPase activity, calcein-AM, 
transcellular  transport  assays  and  in  vivo  observations  (Adachi  et  al.  2001;  Polli  et  al.  
2001; Smith et al. 2001, Feng et al. 2008). For example Adachi et al. (2001) found poor 
correlation of p-glycoprotein ATP hydrolysis measurements and in vivo efflux ratios in 
mice. This poor correlation with in vivo is not unexpected as the ATPase activity and 
calcein-AM assays measure different aspects of transport than the common in vivo 
methods. However, ATPase activity assay results for a group of antipsychotic drugs 
were in line with published data from other studies (Boulton et al. 2002). Shirasaka et 
al. (2006) proposed that some of the differences in results could be due to the 
concentration of drug interfering with the detection of phosphate levels, which could be 
accounted for with additional correction. According to Polli et al. (2001), membrane 
permeability  and  affinity  of  the  drug  can  affect  the  results  of  the  calcein-AM  and  
ATPase  activity  assays  and  that  these  assays  are  most  suited  for  compounds  with  
permeabilities over 300 nm/s.  
 
18 
 
An important drawback of both assays is that they do not measure the transport step or 
movement of drugs across the membrane (Feng et al. 2008). In addition, the calcein-
AM assay specifically detects inhibitors of transporters and not all inhibitors are 
transported substrates and vice versa. In both cases other methods are subsequently 
needed to evaluate whether actual transport takes place or not. Interpretation of results 
should take into consideration the possibility of variation of transporter expression 
between batches as well as interspecies differences. Despite these limitations both the 
calcein-AM and ATPase activity assay can be used as fast screening techniques in early 
drug development (Schwab et al. 2003).  
 
 
4 IN VIVO METHODS 
 
In vivo studies are an important part of all drug development and they are the ultimate 
test of hypotheses and predictions made from in vitro studies. Compared to simplified in 
vitro situations, in vivo studies offer a look at the body as a whole and essentially help 
to  scale  and  assess  the  significance  of  different  factors,  though  interpretation  must  be  
done carefully. With different techniques, it is also possible to study specific aspects of 
drug distribution depending on the study question. Although in vivo methods are not 
usually used in early stages of drug discovery, some of the simple methods, such as the 
in situ brain perfusion, could possibly be used to screen drugs with low to medium 
throughput (Cisternino et al. 2001) 
 
The problem with blood-brain barrier studies is the challenge of studying brain 
distribution in humans. Even current non-invasive technologies, like positron emission 
tomography (see 4.4), have their limitations in human studies, so obtaining a reliable 
time course in the human brain can be problematic (Westerhout et al. 2011). The need 
to measure brain concentrations is sometimes circumvented in both human and animal 
studies by using a measure of effect (Sadeque et al. 2000; Handal et al. 2002; Hamabe 
et al. 2007). The drawback is that for this to be possible, there needs to be a clear CNS-
mediated effect which increases linearly with dose and which can be readily recorded.  
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Instead of humans, rodents are often used in BBB permeation studies, because they can 
be sacrificed and brain tissue collected. To study the role of active transport in vivo, 
inhibitors that induce chemical knockout as well as transporter-gene deficient animal 
models are needed. Because animals are used as a surrogate to make predictions of 
distribution in humans, it is crucial that transporter expression and substrate specificity 
are comparable between species.  
 
Chemically induced knockout provides insight to transporter function and it is 
applicable to human studies. The problem is the lack of selective and potent inhibitors 
(Choo et al. 2000; Yang et al. 2008). Many transporter inhibitors also affect metabolic 
enzymes which is an undesirable characteristic. The use of unselective inhibitors can 
result in wrong interpretations of data as was exemplified by Bourasset et al. (2003) 
with morphine-6-glucuronide, which they only correctly identified as a p-glycoprotein 
non-substrate in knockout animal studies. Toxicity may also be a limiting factor in the 
dosing of modulators (Yang et al. 2008). If total knockout is not achieved, it is 
important to know the degree of inhibition to be able to draw meaningful conclusions.  
 
In rodents, p-glycoprotein is coded by two separate genes, mdr1a and mdr1b, which are 
located distinctly in different tissues (Croop et al. 1989). Together they are thought to 
serve the same role as the MDR1 gene product in humans, based on the similar tissue 
distribution. Several different knockout mouse models are available to study p-
glycoprotein mediated transport (Schinkel et al. 1994; Schinkel et al. 1997). The 
assumption in studies with these knockout animals is that the only difference between 
the strains is the lack of functional p-glycoprotein. None of the generated p-glycoprotein 
knockout mouse strains (mdr1a, mdr1b and mdr1a/b) show any abnormal signs in 
physiology, vitality, fertility or development (Schinkel et al. 1994; Schinkel et al. 1997).  
 
An aberration in the mdr1a knockout mice is the upregulation of the mdr1b gene in the 
kidney and liver (Schinkel et al. 1994). In brain distribution studies, this is unlikely to 
have major significance if brain concentrations are normalized to plasma 
concentrations. The mdr1a (-/-) or mdr1a/b (-/-) mice are most commonly used in brain 
studies, because mdr1a is the form of p-glycoprotein expressed at the BBB (Schinkel et 
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al. 1994). In addition to the generated mdr1a knockout mice, a naturally mdr1a-
deficient strain of CF-1 mice has been identified and has subsequently been used in 
studies (Umbenhauer et al. 1997). Due to the natural occurrence of the polymorphism, it 
could prove to be a more realistic model. Even so, in this natural mutant model, bcrp 
seems to be upregulated as shown in in situ perfusion studies and differing mRNA 
levels (Cisternino et al. 2004a). In addition to this mouse strain, a p-glycoprotein gene 
mutation that results in a truncated, non-functional protein has been identified in Collie 
dogs sensitive to ivermectin (Mealey et al. 2001).  
 
Knockout mice models have also been generated for other transporters including mrps 1 
– 4 and bcrp for use in transporter studies (Lorico et al. 1997, Kruh et al. 2007). Some 
of these transporters may, however, be more significant in determining excretion or 
distribution of substrates to tissues other than the brain as the expression levels of mrps 
in the mouse brain are very low (Kamiie et al. 2008). Also, for example, mrp1 mediated 
luminal efflux at the BBB was not shown to occur in in situ perfused mice (Cisternino 
et al. 2003b).   
 
4.1 Tissue Distribution Studies 
 
A simple method of characterizing drug distribution in laboratory animals is to sacrifice 
animals after a defined period of time after dosing and subsequently collect the tissues 
of interest (Schinkel et al. 1994; Doran et al. 2005). The amount of accumulated 
radiolabeled (or non-labeled) drug can then be analyzed from homogenated tissue. This 
type of tissue analysis is also a part of the in situ brain perfusion technique (see 4.2). 
 
The method can be used either as a single time-point study or animals can be sacrificed 
at different times to obtain a pharmacokinetic profile (Doran et al. 2005; Kalvass et al. 
2007). The use of knock-out animals makes it possible to determine overall effects of 
transporters on distribution. Different routes of administration are possible, but for brain 
permeation studies, the intravenous injection offers the least ambiguous components, 
because it avoids first-pass metabolism.  Tissue distribution studies give a good 
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overview of drug disposition, but have limited applicability to characterization of 
specific processes. 
 
Tissue distribution studies are relatively easily performed, but have the need for many 
animals, especially when defining several time points and using both wild-type and 
knockout animals. From the results, the concentration ratio between brain and blood or 
plasma (Kp) can be calculated. Kp values  calculated  from  AUC  or  steady-state  values  
are more meaningful than single time point values and therefore the use of these is 
encouraged. The drawback of the method in terms of calculating AUC is that data for a 
single AUC value is not from one animal.  
 
The tissue distribution studies only give the total amount of drug in tissues. Therefore, 
in addition to being examined on its own, the Kp value can be combined with in vitro 
derived fraction unbound values for drug in brain and plasma to estimate the unbound 
Kp value (Kp,uu) (Becker and Liu 2006). This can be used to make assumptions of 
possible active transport mechanisms. The Kp values of knockout and wild-type animals 
can be compared to obtain the efflux ratio (ER) of the transporter in question to give an 
idea of the magnitude of transporter effects (Doran et al. 2005).  
 
4.2 In Situ Brain Perfusion 
 
The in situ brain perfusion is a method that measures the movement of drug into the 
brain during a short period of time in the range of tens of seconds to minutes (Takasato 
et al 1984). In the method, the left hemisphere of the laboratory animal, usually mouse 
or rat, is perfused by a drug solution via the left common carotid artery. After this the 
brain tissue is harvested and the amount of drug in the tissue is determined. Due to the 
short duration of the experiment, it can be assumed that the movement of drug happens 
only in the direction from blood to brain (Dagenais et al. 2004). The parameter that is 
calculated is the Kin (also referred to as CLup), depicting the initial value of drug uptake. 
It is defined by equation 2: 
??? =  ??????????? × ??    (2) 
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where Xbrain is the amount of drug in the brain, corrected for drug in blood vessels, Cperf 
is the concentration of drug in the perfusate and T is the duration of perfusion 
(Cisternino et al. 2001). By integrating flow to this parameter, the permeability-surface 
area product (PS) can also be estimated with the Crone-Renkin equation (3) (Takasato 
et al. 1984): 
?? ? ???? ? ??(1? ??????)   (3)  
where Fpf is the regional cerebral flow of the perfusion liquid often taken as the Kin of 
diazepam, a flow limited compound. 
 
The  advantage  of  this  method  is  that  it  is  not  affected  by  systemic  processes  such  as  
absorption or metabolism (Takasato et al. 1984; Cisternino et al. 2001). It is suitable for 
a  wide  range  of  Papp-values, ranging from 10-4 to 10-8 cm/s. The short duration of the 
perfusion and optimized flow rates means that the integrity of the BBB is maintained 
during the experiment. The composition of the perfusate can be varied to contain buffer, 
plasma proteins or blood, to study the effects of plasma protein binding for example. A 
combination of drugs can be co-perfused to study drug-drug interactions. It is also 
possible to study saturation of transport with increasing amounts of drug in the perfusate 
and use this data to determine Michaelis-Menten parameters of active transport 
(Cisternino et al. 2003a; Cisternino et al. 2004b). 
 
The  drawback  of  the  method  is  that  it  only  measures  the  total  amount  of  drug  in  the  
brain (Takasato et al. 1984). Although more simple than microdialysis, the in situ brain 
perfusion also requires some surgical procedures. A major disadvantage is that like in 
tissue  distribution  studies  (see  4.1)  only  one  sample  is  obtained  for  each  animal.  Care  
should be taken when choosing perfusion concentrations to avoid saturating active 
transport, which could obscure results (Summerfield et al. 2007). Also, for drugs having 
low permeability and slow equilibration across the blood-brain barrier, the method may 
underestimate the effects of active mechanisms due to the lack of equilibrium (Zhao et 
al. 2009b). The method may therefore be more suitable for ranking compounds 
according to permeability than predictions of steady-state kinetics (Dagenais et al. 
2001). Calculation of flow-corrected permeability with the Crone-Renkin equation can 
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also prove to be problematic for compounds that have flow-limited permeability, but 
some methods incorporating ionization data of such compounds have been suggested to 
overcome this problem (Avdeef and Sun 2011).  
 
The influence of transporters on the uptake of drugs can be studied with the in situ brain 
perfusion using either knockout animal models or inhibitors (Cisternino et al. 2001). Of 
these two, the knockout model seems to be more sensitive in detecting p-glycoprotein 
effects. Because the in situ perfusion technique describes processes of drug moving into 
the brain, it will only detect changes in the active influx and influx hindrance and not in 
efflux clearance (Cisternino et al. 2003b). It is therefore not suitable for studying all 
transporters. Influx hindrance has been suggested as one of the mechanisms of action 
for p-glycoprotein, and thus the in situ perfusion is suitable for studying its effects. The 
method has been used widely for different compounds in both normal and p-
glycoprotein deficient animals and has shown significant differences in BBB 
permeability between these strains (Cisternino et al. 2001; Dagenais et al.  2004; 
Summerfield et al. 2007; Dagenais et al. 2009). 
 
4.3 Brain Microdialysis 
 
The intracerebral microdialysis method is a complex and invasive method that is able to 
measure unbound concentrations of compounds in the brain interstitial fluid (ISF) (de 
Lange et al. 1999). A microdialysis probe is implanted into the brain of a laboratory 
animal and perfused with a physiological solution at a constant flow rate. The technique 
is based on the passive diffusion of compounds through a semi-permeable membrane 
according to concentration differences. Coupled with plasma pharmacokinetics, the 
brain concentrations can be used to draw conclusions of BBB permeability. Although 
often used in rats, the method is applicable to mice, which makes it possible to use the 
available mouse models of p-glycoprotein deficiency.   
 
Although the principle is simple, microdialysis is extremely sensitive to study 
conditions (de Lange et al. 1997). The effects of probe placement, its shape, perfusate 
composition and flow rate, as well as interaction between the probe and drug all need to 
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be carefully considered. The surgery needed to implant the probe could affect BBB 
integrity, but a 24 hour recovery period seems to minimize tissue damage. A critical 
step is relating the dialysate sample concentrations to concentrations in the extracellular 
fluid (de Lange et al. 1997; de Lange et al. 1999). This should be done carefully, as 
changes in active transport can change the in vivo recovery and could result in false 
results. Sensitive analysis methods are often needed due to low concentrations and small 
sample  volumes.  The  sample  describes  the  average  concentration  in  the  brain  
extracellular fluid between sampling times which can be a problem for compounds with 
very short half-lives. 
 
Despite the complexities and the drawbacks of microdialysis, it remains the sole method 
that is able to measure unbound, pharmacologically relevant concentrations in the brain 
(de Lange et al. 1999). The number of animals needed per study is reduced compared to 
in situ perfusion for example, as a concentration-time profile is gained for each animal. 
With regard to pharmacokinetic modeling, it is useful because both inward and outward 
fluxes at the blood-brain barrier can be determined with data-fitting (Boström et al. 
2006, Kalvass et al. 2007). Local concentrations can be measured depending on the 
implantation site of the probe and for example the effects of tumors on the BBB can be 
studied as well (de Lange et al. 1999). Altogether, the brain microdialysis is an 
important and unique method for the determination of brain concentrations and it has 
been used to study many CNS active compounds like diazepam, morphine and its 
metabolites, carbamazepine and risperidone, to name a few (Dubey et al. 1989; Tunblad 
et al. 2003; Bourasset and Scherrmann 2006; Liu et al. 2009). 
 
4.4 Positron Emission Tomography (PET) 
 
A useful noninvasive method of quantitatively characterizing the brain distribution of 
drugs is positron emission tomography (PET) (Hendrikse et al. 1998). It is based on the 
use of radiolabeled drugs that emit positrons (Hendrikse et al. 2002). Drugs are labeled 
with atoms, often [11C], containing excessive protons in the nucleus, which makes them 
unstable and the proton liable to decay resulting in a neutron and a positron.  The 
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contact of positrons with electrons results in ?-rays, which can be detected outside the 
body with the PET apparatus. 
 
Due to the sensitivity of detection, only tracer doses are needed, which increases the 
safety of the studies (Sasongko et al. 2005). Although the exposure to radioactivity is an 
unwanted quality in human studies, the amount of radiation exposure remains small. 
The relevance of tracer doses should nonetheless be considered carefully when studying 
saturable processes. The greatest advantage of the technique is its noninvasiveness and 
the possibility of attaining a distribution profile over time (Upton 2007). It is also one of 
the very few methods that are suitable for distribution studies in the human brain. With 
PET  there  is  also  an  opportunity  of  visualizing  concentrations  in  discrete  areas  of  the  
brain as well as measuring regional blood flow.  
 
The drawback of PET is that it is not suited for screening and requires expensive 
equipment as well as radioactive test compounds and therefore its use in drug discovery 
may be limited. The short half-life of radioactive labels, for example [11C], may limit 
the duration of the study (Westerhout et al. 2011). The use of anesthesia in animal 
studies can affect physiology, for example blood flow, and possibly results, which 
should be considered. For small animals such as rodents, the size of the animal may 
restrict the sensitivity of the assay (Hendrikse et al. 1998). It should also be noted that 
only total brain concentrations are recorded and that some signal can be due to 
metabolites (de Lange 1999).   
 
PET enables studies of active transport in humans, both patients and volunteers, with 
inhibitors, as well as studies in (knockout) animals. The use of PET in BBB and brain 
distribution studies is receiving increasing interest. Several studies have been conducted 
with  [11C]-verapamil as a typical p-glycoprotein substrate and cyclosporine A as an 
inhibitor (Hendrikse et al. 1998; Hendrikse et al. 2002; Sasongko et al. 2005) with 
success. Use of [11C]-verapamil in PET scans has also been suggested as a tool for 
studying p-glycoprotein function: PET could have application in detecting p-
glycoprotein mediated drug resistant tumors and studying the inhibitory effects of drugs 
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as well as the consequences of polymorphisms of transporters (Hendrikse et al. 2002; 
Sasongko et al. 2005). 
 
 
5 IN SILICO METHODS 
 
The availability of large virtual compound libraries in drug development results in the 
need for efficient screening systems. Because, especially for CNS targeted drugs, being 
a p-glycoprotein substrate is seen as a potentially negative characteristic, in silico 
models have been developed to screen out potential substrates. With more complicated 
pharmacokinetic models the relationships between saturable active and passive 
transport, in addition to factors like protein binding, can be examined. Also 
incorporation of pharmacokinetic data in the CNS into models of pharmacodynamic 
action (PK/PD modeling) can be used to simulate drug effects.  
 
5.1 QSAR Models to Predict P-Glycoprotein Substrates 
 
Computer models, based on the structural and physicochemical properties of drugs, 
developed for overall blood-brain barrier permeability have had little success in 
predicting permeability for p-glycoprotein substrates (Liu et al. 2004). The descriptors 
of the models mainly reflect lipophilicity of compounds, which means that they are 
unable to describe active processes. Therefore, efforts have been made to construct 
more specific, quantitative structure-activity relationship (QSAR or sometimes 
structure-property QSPR) models to identify p-glycoprotein substrates and thus guide 
decision making in lead compound selection. Ideally the output from QSAR models 
could also be used as input in more sophisticated pharmacokinetic models. 
 
Several approaches relating to both calculation of descriptors as well as categorization 
of compounds have been used to predict p-glycoprotein substrates based on molecular 
properties. Efflux ratio, determined in in vitro transcellular transport studies (see section 
3.3), is often used to discriminate substrates and non-substrates for subsequent modeling 
(Gombar et al. 2004; Crivori et al. 2006; Zhang et al. 2007). Even though QSAR models 
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based on ER classification have good prediction (roughly 80 %), their main pitfall is 
that they are in fact, only predictors of results of the monolayer studies. The problematic 
is illustrated for example by the fact that three common substrates of p-glycoprotein, 
verapamil, quinidine and loperamide were all designated as non-substrates in the dataset 
of Crivori et al. 2006.  For p-glycoprotein studies the MDR1-MDCKII cells used by 
Gombar et al. (2004) seems more relevant than the Caco-2 cell line used in some 
studies, because it has less additional transporters.  
 
Other groups have used more diverse sources containing both in vivo and in vitro data 
for the classification of compounds (Seelig 1998; Penzotti et al. 2002; de Cerqueira 
Lima et al. 2006). Penzotti et al. 2002 reported a pharmacophore based QSAR model 
which had a prediction success rate of only 63 % in the test group, whereas de 
Cerqueira Lima et al. (2006) were able to construct a model with better prediction for 
the same compound set using combinatorial QSAR. Testing four different classes of 
predictors with four different QSAR methods yielded success of 81 % in the test set by 
the best model. 
 
The drawback of the QSAR approach is that its predictive accuracy relies on the 
relevance of the method used to generate data. Ideally the study should measure only p-
glycoprotein interaction, but such studies are impossible to conduct. What must also be 
kept in mind is that QSAR model predictions are reliable only for compounds that have 
properties in the range of the compound set used to build the model (Gombar et al. 
2004). In the combinatorial QSAR approach de Cerquiera Lima et al. 2006 also 
illustrated the importance of validation of models with test sets as many of the proposed 
models worked well in training sets, but failed during testing. 
  
The prediction of compound interaction with p-glycoprotein is complicated by the fact 
that  the  high  resolution  crystallization  of  membrane  proteins  is  difficult  and  the  
estimation of the structure of p-glycoprotein has relied on protein homology modeling 
(Ecker et al. 2008). Even though studies have used known substrates as a basis for 
elucidating p-glycoprotein interaction, no certain pharmacophore for p-glycoprotein 
substrates has been identified. A few features have however been identified as typical 
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properties. Hydrogen bonding properties have been suggested by Seelig (1998) and 
Crivori et al. (2006) to play an important role. The molecular E-State, which describes 
molecular bulk, was defined as a rough discriminating factor between substrates and 
non-substrates (Gombar et al. 2004). In the compound set used by Zhang et al. (2007), 
p-glycoprotein substrates tended to be branched molecules with electron deficient 
aromatic rings and possibly containing tertiary nitrogen atoms. Hopefully in the future 
robust models built with more accurate data sets will increase the usefulness of QSAR 
in screening p-glycoprotein substrates. The prediction of kinetic parameters based on 
molecular properties is also interesting, but may be unachievable due to binding site 
complexity. 
 
5.2 Pharmacokinetic Models of Drug Disposition into the Brain 
 
An in-depth look at the role of p-glycoprotein or other transporter mediated efflux is 
necessary for making informed decisions in drug development. Only few publications 
are available in this field concerning the BBB, probably owing to the lack of data 
available for the construction of physiologically based pharmacokinetic (PBPK) models 
focusing on brain distribution. Many of the available models of blood-brain barrier 
efflux are mainly based on theoretical simulations (Hammarlund-Udenaes et al. 1997, 
Mahar Doan and Boje 2000, Syvänen et al. 2006). Other publications on brain PK 
modeling have so far focused on fitting experimental pharmacokinetic data. Although 
these studies have given insight into the important factors governing brain partitioning 
and the role of active transport mechanisms, there is also a need for predictive models 
of brain distribution in early drug development.   
 
Empirical models have been used to study different aspects of drug brain distribution. 
For example, a brain PBPK model published by Liu et al. (2005) was constructed to 
study the effects of BBB permeability and unbound brain and plasma concentrations on 
time to reach steady-state. Although the model was simplified and no discrimination 
was made between active and passive processes, they were able to demonstrate that the 
time to reach steady-state is dependent on the product of brain permeability (PS) and 
fraction  of  unbound  drug  in  the  brain.  Data  fitting  can  also  be  useful  studying  
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underlying mechanisms of drug transport, as shown for example by Bourasset and 
Schermann (2006) who used modeling to examine possible transport at different 
interfaces in the brain.  
 
In theoretical simulations, simple two or three compartment models have been used to 
describe the movement of drugs from blood into the brain. Hammarlund-Udenaes et al. 
(1997) studied the effects of different influx and efflux conditions on the rate and extent 
of BBB permeability. They showed for example that inward clearance dictates the 
ability of drug to reach the brain. The concentration-time profile in brain is determined 
by the brain elimination rate constant (kout)  in relation to the systemic elimination rate 
constant (kel).  It  was  concluded  that  brain  concentration  is  likely  to  follow the  plasma 
concentration profile due to the small distribution volume in the brain, but that unbound 
brain concentrations tend to be much lower than those in plasma, which was supported 
by microdialysis data.  
 
The influence of different efflux processes on drug concentrations in the brain was 
studied by Syvänen et al. (2006). Using a model with 3 compartments (plasma, 
endothelial cell and brain tissue) the group simulated brain concentrations with different 
combinations of luminal and abluminal efflux enhancement and luminal influx 
hindrance. What they discovered was that partitioning of drug was not influenced by the 
localization of efflux transporter. However the transporter’s mechanism of action is of 
importance, as influx hindrance was found to be the most effective mechanism of 
hampering blood-brain barrier permeation. This was suggested to be an explanation of 
the efficiency of p-glycoprotein, which is thought to act at least partly by the influx 
hindrance mechanism.  
 
Because the blood-brain barrier limits the movement of many drugs into the brain, there 
is often dissociation between unbound plasma and brain concentration, which means it 
may be difficult to relate CNS based pharmacodynamic effects to plasma concentrations 
(de Lange et al. 2005). On the other hand, because direct measurement of brain 
concentration is challenging, there has been interest in using pharmacokinetic-
pharmacodynamic (PK/PD) modeling of CNS drugs and it has been explored for 
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example with opioids (Groenendaal et al. 2007; Kalvass et al. 2007; Groenendaal et al. 
2008). With PK/PD modeling it is not only possible to more comprehensively compare 
drugs of the same class but modeling can take into consideration physiological changes 
in disease states (de Lange et al. 2005). 
 
The future goal of BBB PK modeling is to develop a model based on in vitro 
parameters for the prediction of brain concentrations. Ideally, the data needed for 
predictions should be attained reliably from simple in vitro experiments, saturable 
active transport processes should be integrated into the model and scaling from 
laboratory animals to humans should be possible. This type of model would not only 
give more information on the consequences of active transport and maybe avoid 
discarding promising drug candidates based solely on the fact that they are p-
glycoprotein substrates, but could also decrease the need for animal studies. 
 
Overall, though intriguing, more experimental tools especially aimed at generating data 
for modeling, such as a reliable in vitro model of the BBB, are needed for the 
realization of such an in silico model. Modeling of saturable Michaelis-Menten type 
kinetics requires the determination of kinetic parameters Km and  Vmax. These can be 
generated with available in vitro and in vivo methods, but their accuracy and utility has 
been questioned (Bentz et al. 2005). For scaling, it is important to know protein 
expression in the cell lines used to generate the data. With advances in the 
characterization of human blood-brain barrier and the quantification of protein levels in 
brain microvessels, this type of model could be feasible. Scaling has already been used 
from in vitro to in vivo, in modeling intestinal absorption of p-glycoprotein substrates as 
well as predicting brain to plasma concentration ratios from in vitro ER and fraction 
unbound values (Shirasaka et al. 2008b, Uchida et al. 2011b).  
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6 CONSEQUENCES OF P-GLYCOPROTEIN MEDIATED EFFLUX AT 
THE BLOOD-BRAIN BARRIER 
 
P-glycoprotein at the blood-brain barrier has been shown to have a role in regulating the 
toxicity of certain drugs, such as ivermectin in mice (Schinkel et al. 1994). With 
ivermectin, the effects of p-glycoprotein are beneficial in that it prevents toxicity, but 
for other drugs like HIV protease inhibitors, the transporter can be a hindrance to their 
effects (Kim et al. 1998). On the other hand, part of the reason why loperamide, unlike 
other  opioids,  is  a  useful  anti-diarrheal  medicine  without  CNS  side  effects,  is  that  its  
entry into the brain is hindered by p-glycoprotein (Schinkel et al. 1996). 
 
From a toxicological point of view, p-glycoprotein function and restricted brain 
permeation is important, because the brain is a sensitive organ. Although p-glycoprotein 
is expressed in many organs affecting distribution, it has been shown to have a 
significant effect in particular on brain concentrations (Cordon-Cardo et al. 1990; 
Schinkel et al. 1994). This can be due to the difference in membrane properties of cells 
in  different  tissues  as  well  as  local  drug  concentrations.  For  example,  intestinal  
concentrations after oral ingestion are much higher than plasma or brain concentrations 
and therefore saturation is less likely at the BBB thus increasing significance of p-
glycoprotein. In the case of CNS targeted drugs, brain permeability and transport 
activity needs to be determined early on in development, because it is a critical and 
often limiting factor in their success. Characterization is also important for substrate 
drugs with a narrow therapeutic window, as patients could be at risk for unexpected 
effects with variable p-glycoprotein transport. 
 
On the other hand, there has been interest in the use of inhibitors as a way to improve 
drug permeability into the brain, for the treatment of brain tumors for example (Yang et 
al. 2008). Despite p-glycoprotein deficient mice showing no other abnormalities, 
chemically induced knockout in humans should be regarded with caution. Patients 
needing this type of treatment are likely to be taking other medication, which could also 
be affected by inhibition. Unlike laboratory animals, people are also exposed to a lot of 
potentially harmful substances that they may be protected against by p-glycoprotein. 
32 
 
Ultimately,  even  if  it  were  safe  to  induce  knockout  in  humans,  achieving  it  seems  
difficult and therefore no inhibitor is in clinical use to overcome multidrug resistance 
(Yang et al. 2008). 
 
For many drugs with targets in the CNS, in vivo efflux ratios (ER) determined in mice 
seem to be less than 2, but even those that have higher ratios  can succeed as CNS drugs 
(Doran et al. 2005). An important question is, should promising CNS (or other) drug 
candidates be discarded on the basis of being recognized as p-glycoprotein substrates. 
Classification should be done carefully with the use of several complementary methods 
to be able to give extensive information. Even with the correct classification of drugs as 
substrates, the prediction of brain permeation can be difficult, because the significance 
of p-glycoprotein depends on many factors. Although the importance of p-glycoprotein 
is still unclear, there is a possibility of interaction and therefore the characterization of 
drugs in relation to p-glycoprotein is beneficial in drug development.   
 
6.1 Drug-Drug Interactions 
 
Many studies have focused on drug-drug interactions (DDIs) mediated by a range of 
transporters at the blood-brain barrier, but results have often been inconclusive (Eyal et 
al. 2009). Studies in rodents suggest a possibility of p-glycoprotein DDIs, but 
interpretation and extrapolation to human clinical situations is difficult. The knowledge 
of interspecies variability concerning BBB transport is increasing and for example 
differences between transporter expression levels have been recognized (Kamiie et al. 
2008; Warren et al. 2009; Uchida et al. 2011a). The higher expression of p-glycoprotein 
in mice versus humans could mean that the efflux determined in knockout mice 
overestimates  the  significance  of  p-glycoprotein  in  the  human  brain  and  the  risk  of  
interaction. A similar phenomenon may arise in in vitro cell systems where over-
expression is common. 
 
Other factors may also result in unrealistic significance of drug-drug interactions 
evaluated in mice or rats (Eyal et al. 2009). For example concentrations of drug and/or 
inhibitor used in both in vitro and in vivo studies rarely reflect relevant clinical 
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concentrations. In these cases, inhibition could be overplayed resulting in 
overestimation or transport could be saturated thus giving an underestimation. The use 
of clinically relevant concentrations of inhibitors is supported by a study of Hsiao et al. 
(2006) that showed that similar concentrations of cyclosporine A produced a similar 
inhibitory effect and consequent increase in brain concentrations of verapamil in both 
rats  and  humans.  A  PET  study  examining  species  differences  in  CsA  inhibition  and  
drug distribution into the brain in rats, guinea pigs, monkeys and humans, suggested 
that the significant variability between species was not only due to p-glycoprotein 
differences, but also CsA potency and intra-brain distribution (Syvänen et al. 2009). 
 
Even if similar concentrations are used in different species, differences may arise 
between species in the inhibitory effects of drugs on p-glycoprotein (Suzuyama et al. 
2007). Inhibitors neither show a uniform level of inhibition for all compounds (Rautio 
et al. 2006). Kalvass and Pollack (2007) suggest that the required concentration of 
inhibitor is dependent on the maximal efflux, which can vary between species and 
makes it difficult to find the correct dose for a uniform inhibition level. The effects of 
inhibitors is also dependent on factors like protein binding, which explains the 
difference  in  inhibition  potency  of  cyclosporine  A  and  SDZ  PSC  833  (Lemaire  et  al.  
1996).  
 
The effect of 5 p-glycoprotein inhibitors, used clinically for other indications, on 
digoxin concentration was evaluated in rats and of these drugs only cyclosporine A 
(CsA) increased digoxin brain concentrations significantly (Sugimoto et al. 2011). 
Combining the rat data with in vitro derived Ki-values and therapeutical unbound 
plasma concentrations of the drugs, it was speculated that the risk of this type of DDI at 
the BBB is minimal. In in situ brain perfusion, co-perfusion of inhibitors increased the 
uptake of colchicine and vinblastine (Cisternino et al. 2001). PET studies in humans 
showed a 73 % increase in verapamil transfer into the brain by CsA, but variability was 
large (30–118 %)  (Muzi et al. 2009). In a similar PET inhibition study an increase of 
roughly 80 % in Kp values was reported (Sasongko et al. 2005). 
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P-glycoprotein mediated DDIs are an interesting field, because there is a potential for 
these kinds of interactions due to the large range of substrates and their possible use in 
combination. For example cancer patients often need opioid-based pain medication in 
addition to anti-cancer medicines, of which both groups contain p-glycoprotein 
substrates. However, these DDIs seem unlikely, because even for cyclosporine A, which 
is regarded as one of the most potent inhibitors used in drug therapy, the inhibitory 
effects are modest and variable (Sasongko et al. 2005; Eyal et al. 2009; Muzi et al. 
2009). On the other hand, there may be some interactions that have not yet been 
recognized or that have been misinterpreted to be based on some other mechanism that 
transporter mediated drug-drug interactions. 
 
One of the few studies that suggested a relevant transporter based drug-drug interaction 
in humans showed increased CNS effects of loperamide co-administered with quinidine, 
but even in this study the dose levels were unrealistically high (Sadeque et al. 2000). 
Even though the importance and risk of these types of drug-drug interactions remains 
unclear, the FDA has made recommendations for transporter based interaction studies in 
addition to studies of metabolism based DDIs (Food and Drug Administration 2006). 
Although  at  the  moment  it  seems  that  transporter  mediated  DDIs  are  more  of  an  
exception  than  the  rule,  for  some  drugs  they  could  be  a  source  of  significant  adverse  
effects. 
 
6.2 Interindividual Variability and Pharmacogenetic Factors 
 
Unlike the Collie breed of dogs or CF-1 mice, no inherent functional knockout of p-
glycoprotein has been discovered in humans. There has been much interest in studying 
polymorphism of p-glycoprotein as a way of explaining inter-individual variability in 
drug response at gene level. So far several common single nucleotide polymorphisms 
have been identified (Hoffmeyer et al. 2000). The single nucleotide polymorphisms 
C3435T and G2267T/A have received the most interest although others are likely to be 
involved as well.   
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The distribution of polymorphisms between populations has been investigated and it has 
been noted that for example the frequency of the C3435T polymorphism is significantly 
different between populations of Caucasians, African Americans and the Japanese (Kim 
et al. 2001; Schaeffeler et al. 2001). This could mean diminished absorption and effect 
of p-glycoprotein substrate drugs, like HIV-protease inhibitors, in African populations. 
The effects of these polymorphisms and their significance remain unclear due to 
contradictory study results, and so far they have not been able to incontestably explain 
differences in pharmacokinetics of substrate drugs.  
 
In addition to genotype, concomitantly administered drugs and disease state can affect 
the function of p-glycoprotein. For example the use of chemotherapeutic drugs and anti-
epileptics can lead to the upregulation of p-glycoprotein in tumors and in the brain 
(Dombrowski et al. 2001). The significance of upregulation to drug-resistant epilepsy is 
still unknown, as data on the effect of p-glycoprotein transport on anti-epileptic drug is 
quite contradictory (Baltes et al. 2007; Löscher 2007). It has also been postulated that 
differences in p-glycoprotein function at the blood-brain barrier could predispose people 
to neurological diseases such as Parkinson’s and Alzheimer’s diseases (Furuno et al. 
2002; Vogelgesang 2002; Kortekaas et al. 2005). 
 
The connection between genotype and remission of depression with antidepressants has 
also been studied (Uhr et al. 2008). Brain distribution of citalopram and venlafaxine was 
significantly increased in p-glycoprotein knockout mice and in humans a certain 
polymorphism was linked with the probability of remission.  This could be an indication 
that although many studies have concentrated on p-glycoprotein function and effect of 
genotype on the excretion of drugs in the gut and liver, it is worthwhile to consider also 
the situation at the BBB.  For low permeability CNS drugs, variability in p-glycoprotein 
function  could  alter  the  response  of  the  patient  to  the  drugs.  However,  currently  this  
data is scarce and therefore the inter-individual variability of p-glycoprotein function at 
the BBB requires further research.  
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7 CONCLUSIONS 
 
The permeability of drugs into the brain is an important factor to be considered in both 
CNS and non-CNS drug development. The blood-brain barrier, a unique barrier 
regulating the entry of molecules into the brain, is the rate limiting step in the brain 
permeation of many drugs. As the role of active transporters at the blood-brain barrier 
has been recognized, many different tools, in silico, in vitro and in vivo, have been 
developed and there is consensus that these should be used in parallel with each other to 
gain an overall picture of brain permeation. Especially for simple in vitro studies, one 
method is not sufficient to give insight into the processes.   
 
P-glycoprotein is the most studied and second most prominent transporter at human the 
blood-brain barrier. A lot of effort has been put into studying p-glycoprotein since its 
discovery, even though significance has maybe proved to be lower than first predicted. 
Even with the interest it has received, the effect of p-glycoprotein on drug disposition 
into the brain remains to be elucidated. Many drugs have been classified as substrates of 
p-glycoprotein, but the relevance of this interaction is not always clear. Even with the 
consideration  of  both  passive  and  active  transport,  the  brain  distribution  is  difficult  to  
predict. All in all, characterization of p-glycoprotein substrates is encouraged early in 
drug development, but interpretation of results should be done carefully to avoid 
discarding otherwise promising drug candidates. 
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1 INTRODUCTION 
 
The distribution of drugs into the brain is an important factor to be characterized in drug 
development to confirm the efficacy and safety of drugs. Due to its unique structure, the 
blood-brain barrier, a tight layer of specialized endothelial cells, serves as a gatekeeper 
for many compounds restricting their entry into the brain. In addition to the mechanical 
barrier, metabolic enzymes and a multitude of transporters of xenobiotics and 
endogenous substances further actively regulate distribution of these compounds. Many 
tools have been developed to study drug entry to the brain, but owing to the complicated 
nature of underlying processes, it has sometimes been difficult to interpret findings. 
This taken together with the challenge and expensiveness of measuring concentrations 
in the brain indicates that there is a place for predictive computational models to assess 
brain penetration in early drug development.  
 
1.1 Basic Concepts of Drug Distribution into the Brain 
 
The first step for a drug to exert central nervous system (CNS) effects is to gain entry 
into the brain by crossing the blood-brain barrier (BBB). The impermeable nature of the 
BBB, with its low pinocytic activity and tight junctions, can hinder the entry of drugs 
into the brain and thus the BBB permeability may be the rate-limiting step of brain entry 
for many compounds (Abbott et al. 2010). Lipophilic drugs can permeate the BBB 
passively, but in silico predictions of permeability based solely on physico-chemical 
properties tend to fail for drugs that are substrates for transporters (Liu et al. 2004). 
Therefore a lot of effort has been placed on measuring drug uptake into the brain, 
although it is not the only factor determining the success of CNS compounds 
(Hammarlund-Udenaes et al. 2008). 
 
There  are  several  different  equilibration  steps  present  as  a  compound  enters  the  brain  
(Hammarlund-Udenaes et al. 2008). First, drug from the blood circulation will enter the 
interstitial fluid (ISF) in the brain and from there, distribute into the intracellular fluid. 
During this equilibration over membranes there is also an ongoing balance of unspecific 
drug binding in these compartments. The equilibration between cells is not only 
dependent on the passive diffusion, but can also be affected by active influx and efflux. 
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To make matters more complicated, unbound drug may be cleared from the ISF by bulk 
flow or distributed from blood via the blood-cerebrospinal fluid barrier into the 
cerebrospinal fluid (CSF). Metabolism of drugs in the brain is also possible as several 
CYP450 enzymes have been detected in both brain cortex and the BBB (Dauchy et al. 
2008).  
 
Due to the existence of numerous different processes in the brain, one should always 
consider which different aspects of distribution experimental procedures measure and 
how the parameters obtained with them should be interpreted (Hammarlund-Udenaes et 
al. 2008) (Figure 1). The classic parameter used to measure drug entry into the brain is 
the Kp (sometimes noted in the logarithmic form as logBB) that is the ratio of total drug 
concentration in the brain (Cbrain) versus that in plasma (Cplasma) (Equation 1). 
?? =  ??????
???????
= ????????
?????????
    (1) 
where AUCbrain and AUCplasma are the area under the concentration-time curve for the 
brain and plasma respectively. The Kp is a measure of drug partitioning between the 
blood and brain, but it does not give meaningful information unless it is determined at 
steady-state or alternatively using the AUC. It is also a complicated parameter to 
interpret as it is influenced not only by rate and extent of distribution, but also binding 
of the drug in blood and brain. 
 
A certain Kp value on its own is not an indication of a successful CNS compound, as 
values between 0.06 and 24 have been reported for 33 established CNS agents (Doran et 
al.  2005).   For  many of  these  compounds,  the  Kp value was greatly influenced by the 
unspecific binding of drugs to brain and plasma (Maurer et al. 2005). This was true 
especially for basic drugs. Therefore much of the differences in Kp values  may in  fact  
arise from differences in drug tissue binding and not blood-brain barrier penetration.  
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Figure 1. Schematic representation of drug partitioning from plasma into the brain. The 
parameters used commonly to describe drug distribution into the brain and the 
experimental methods used for their determination are shown. 
 
Due to the confounding factors making Kp a difficult parameter to interpret, the use of 
unbound concentrations to describe the steady-state distribution of drugs into the brain, 
yielding what is called Kp,uu, is recommended (Hammarlund-Udenaes et al. 2008). At 
steady-state, Kp,uu can be defined as (Equation 2): 
??? ? =  ??? ???????? ????? = ????? ????????? ????? = ?????????    (2) 
where Cu,brain and  Cu,plasma are the unbound drug concentrations in brain and plasma 
respectively, CLin is  the  clearance  of  drug  from blood to  brain,  CLout is the clearance 
from  brain  to  blood  and  AUCu,brain and AUCu,plasma the area under the unbound 
concentration curve.  
 
Unlike the Kp, interpretation of Kp,uu is not confounded by non-specific binding 
(Hammarlund-Udenaes et al. 2008). The use of unbound concentrations is also 
encouraged as it is a better description of the availability of drug to interact with its 
target in the brain and cross membranes according to the free drug hypothesis. Because 
at steady-state the Kp,uu is  equal  to  the  ratio  of  inward  (CLin) and outward (CLout) 
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clearance, the contribution of active transport to equilibrium can be assessed by looking 
at the Kp,uu value.  A Kp,uu of unity means that the drug is either not affected by active 
transport or that both influx and efflux are of the same magnitude. A Kp,uu value below 
one is a sign of dominant efflux and a value greater than one is a sign of influx. 
 
The problem with Kp,uu is that it can only be measured directly with the brain 
microdialysis technique (de Lange 1999). Because the unbound concentration (Cu) is 
the product of the total concentration and the fraction unbound (fu) in the same tissue, 
the Kp,uu can also be defined as: 
??? ? = ?????????????????????????????? ? ?? × ???????????????  (3) 
where  fu,brain and  fu,plasma are the unbound fractions of drug in brain and plasma 
respectively (Hammarlund-Udenaes et al. 2008) (Equation 3). This equation shows the 
possibility of predicting Kp,uu values by combining Kp with in vitro  determined fu 
values (Becker and Liu 2006). The fu,plasma/fu,brain ratio can be used directly to estimate 
Kp assuming that only passive processes govern BBB penetration (Maurer et al. 2005). 
In this approach, a significant deviation of the prediction (over 3-fold) from the in vivo 
derived Kp can be a sign of active efflux or influx (Kalvass and Maurer 2002, Becker 
and Liu 2006).  
 
In addition to looking at the Kp,uu, transporter effects on the brain distribution of drugs 
can be evaluated by comparing Kp values  from  wild  type  (Kp,WT) and transporter-
knockout (Kp,KO) animal studies (Equation 4) (Doran et al. 2005). The parameter 
considered in these studies is known as the efflux ratio (ER). 
?? = ??? ?
??? ?
    (4) 
Many compounds have been shown to have increased distribution into the brain in p-
glycoprotein knockout mice, but for CNS compounds, the impact seems to be minimal 
(Doran et al. 2005). It should be kept in mind that even CNS compounds can exhibit 
high ER value indicating extensive efflux and still be successful if their potency is 
sufficient. A good example of this is the antipsychotic risperidone and its metabolite 9-
OH-risperidone, which have in vivo ER values of 10 and 17, respectively.  
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Hammarlund-Udenaes et al. (2008) highlighted two other important parameters of brain 
distribution, Vu,brain and  CLin, in addition to the Kp,uu,.  Whereas  the  Kp,uu describes  the  
partitioning of drug between the brain and blood, the Vu,brain measures drug distribution 
within  the  brain.  The  advantage  of  Vu,brain is that it can be determined in vitro by the 
brain slice technique, where thinly sliced (300-400 ?m) brain samples are incubated in 
test compound solution (Becker and Liu 2006, Friden et al. 2007). It can also be 
calculated from microdialysis data if the total concentration of drug in brain is also 
quantified (Hammarlund-Udenaes et al. 2008). The value of Vu,brain can be compared 
with physiological volumes of the brain interstitial fluid or total volume, to assess the 
distribution of the compound into the brain parenchymal cells. 
 
The CLin term (sometimes noted as PS, the permeability-surface area product) is used to 
describe the rate of uptake into the brain. It can be measured with several techniques, 
but it is most commonly determined with the in situ brain perfusion method or 
calculated from microdialysis data (Takasato et al. 1984, de Lange et al. 1999). The in 
situ brain perfusion actually gives a value called Kin, which is the flow-dependent 
permeability that should be transformed into the PS value with the Crone-Renkin 
equation for high permeability flow-limited compounds (Takasato et al. 1984).  
 
The CLin gives  an  idea  of  the  time  it  takes  for  a  drug  to  reach  equilibrium,  as  this  is  
dependent on the product of CLin and  fu,brain (Liu et al. 2005). For continuous 
medication, this characteristic is not necessarily of great importance as long as suitable 
concentrations are achieved over time, but for drugs intended for acute alleviation of 
symptoms, for example antiepileptic drugs, fast permeation is critical. However, as the 
fu,brain is also a determining factor of equilibrium, a drug with low permeability may 
achieve this state quickly if binding in brain tissue is low. 
 
Many of the parameters described above are measured in vivo, but in vitro tools for 
studying aspects of brain penetration have also been developed in order to increase 
throughput of experiments as well as decrease costs and need for animals (Gumbleton 
and Audus 2001; Mahar Doan et al. 2002). The measurement of apparent BBB 
permeability (Papp) with in vitro cell models has been of great interest, but brain 
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endothelial cell derived cell lines have shown disappointing results so far, due to their 
leakiness and loss of transport protein activity (Gumbleton and Audus 2001). 
Transcellular monolayer studies also have application in the determination of the role of 
transporters (Polli et al. 2001). Common practice is to determine the in vitro efflux ratio 
(ER) in transfected cell monolayers, by measuring permeabilities across the cell 
membrane in both directions and calculating the ratio of these permeabilities. 
 
1.2 Perspectives on Pharmacokinetic Modeling of the Blood-Brain Barrier 
 
The pharmacokinetic (PK) models of the blood-brain barrier that have been published 
and the kind of information they have produced are discussed in the accompanying 
literature review. Briefly, predictive models of brain distribution are not yet widely 
available and previous reports cover mainly empirical or theoretical brain PK modeling 
although a blood-brain barrier package has recently been added to the commercial 
modeling software SimCyp (SimCyp Limited, United Kingdom). It seems that 
currently, a major problem with pharmacokinetic modeling in this field is the lack of 
suitable data for model validation.  
 
The trend in blood-brain barrier and brain distribution studies has been to concentrate 
on simple methods used to measure only a single feature of drug distribution. As 
discussed  in  section  1.1,  only  in  recent  years  have  we  really  begun  to  understand  the  
mechanisms and relationships between different processes governing the distribution of 
drugs into the brain. This is partly accredited to the kinetic simulations that have 
concentrated on different aspects of brain distribution (Hammarlund-Udenaes et al. 
1997, Liu et al. 2005, Syvänen et al. 2006). Now that the meaning of in vivo measured 
parameters is better understood, it should be possible to use these methods or 
corresponding in vitro methods to generate data and build brain PK models. 
 
The minimal parameter requirements for PK models of brain distribution, is the 
knowledge of systemic kinetics, unbound fractions of the drug in brain and plasma as 
well as data concerning blood-brain barrier permeation, some of which can be 
reasonably easily measured. There are, however, always many variables in experimental 
setups that could affect the outcome of the study and the error could be multiplied when 
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the same value is used in the model. Common problems with current BBB techniques 
are calculation of permeability from in situ perfusion for lipophilic compounds, 
extrapolation of in vitro efflux data to in vivo, relevance of knockout animal models, to 
name a few (Chen et al. 2003; Avdeef and Sun 2011). So even with the current 
methods, it is challenging to generate data that unambiguously represents the parameter 
in question.  
 
Another problem in making predictions from these models is the species differences 
which are evident, but the definitive significance of this variability is unknown. It is 
likely that differences are both quantitative and qualitative. For example slight 
differences in the amount of specific transport proteins have been found between 
monkeys, humans and mice (Ohtsuki et al. 2011). There seems to also be interspecies 
differences in the substrate specificity or affinity of substrates between transporters of 
different species at least in in vitro systems (Yamazaki et al. 2001; Katoh et al. 2006)  
 
Active transport proteins, like p-glycoprotein, play an important role for many 
compounds at the BBB and therefore knowledge of the passive permeability only is not 
sufficient to predict permeation into the brain (Schinkel et al. 1996). However, at the 
moment, active components are rarely discriminated in brain PK models and 
inward/outward clearances only present a combination of active and passive processes. 
In vitro cell models have been used to determine efflux ratios in monolayers, but some 
current models can also be used to determine Michaelis-Menten kinetic parameters of 
transport either directly or indirectly (Shirasaka et al. 2006, Shirasaka et al. 2008). The 
determination of Km,  which  describes  the  affinity  of  drug  to  the  efflux  protein,  is  
however problematic as binding site concentrations are difficult to measure. In addition 
to these types of problems, scaling factors may also be needed to quantitatively predict 
efflux in another setting where expression of the efflux protein is most likely to be 
different.  Scaling  may  also  be  needed  for  the  simpler  ER,  which  describes  the  
magnitude of non-saturable active transport. 
 
So far the transporter that that has undoubtedly received the most attention is p-
glycoprotein, but it is by no means the only transporter modulating blood-brain barrier 
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permeability (Dauchy et al. 2008; Uchida et al. 2011a, Shawahna et al. 2011). Recently 
the breast cancer resistance protein (BCRP) has been recognized as the most prominent 
transporter  at  the  human BBB (Uchida  et  al.  2011a).  Characterization  of  the  function,  
substrate specificity and expression of BCRP and other transporters expressed at the 
blood-brain barrier, is an important area still to be investigated.  
 
For PK models of human brain distribution, the development of imaging techniques like 
positron emission tomography (PET) is a key element. The increase in availability of 
this type of imaging data will enable the validation of human models. Suitable PET 
tracers for studies of transporter function have been developed and inhibition studies 
have been carried out to test the possibility of drug-drug interactions (Hendrikse 1998; 
Sasongko et al. 2005). PET data has also been used to compare and validate in vitro 
models  of  BBB  permeation  with  human  data  (Josserand  et  al.  2006;  Mabondzo  et  al.  
2010). 
 
 
2 AIM OF THE STUDY 
 
The  aim of  this  study  was  to  construct  a  simple  pharmacokinetic  model  of  the  blood-
brain barrier to describe the pharmacokinetic profile of p-glycoprotein substrate drugs in 
the brain as well as to investigate the possibility of replacing in vivo parameters in the 
model with in vitro derived values. Specific aims of the study were to: 
1) Build a pharmacokinetic model of the BBB using in vivo data and simulate brain 
concentrations of drugs 
2) Estimate interspecies variability in Kin and  fu,brain by studying correlation of 
published rat and mouse values   
3) Examine correlation of in vitro ER values from different studies  
4) Test correlation between in vitro and in vivo ER 
5) Simulate an in vitro transcellular monolayer experiment to study the effect of 
passive permeability and Michaelis-Menten kinetic parameters on ER 
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3 MATERIALS AND METHODS 
 
3.1 Data  
 
All the data used in the model was taken from literature. A large range of publications 
was reviewed for suitable data. Focus was on the critical parameters for the model: Kin, 
ER  and  fu. The availability of brain concentration data/microdialysis data limited the 
choice of compounds to be modeled. In light of the possibility of using in vitro values in 
the model, data on transcellular monolayer studies in MDR1 transfected Madin-Darby 
canine kidney (MDCKII) cells was also examined. Altogether, the data in this study 
mainly concentrates on four publications (Polli et al. 2001, Mahar Doan et al. 2002, 
Doran et al. 2005 and Summerfield et al. 2007) that have examined broad compound 
sets of mainly CNS targeted drugs. 
 
3.2 Software 
 
The simulations were performed using STELLA™ software version 9.0.1 (isee systems, 
USA) with the Runge-Kutta 4 algorithm. Simulations were run with the lowest possible 
time interval (DT). Matlab™ version 7.10.0 (R2010a) (MathWorks, USA) was used to 
calculate linear regression for the correlation studies and to visualize data. Microsoft™ 
Office Excel 2007 (Microsoft, USA) was used to handle the data from the in vitro 
simulations and calculate the ER values. 
  
3.3 Structure of the Pharmacokinetic Model  
 
The pharmacokinetic (PK) model consists of 2 compartments depicting the brain and 
blood (Figure 2). No separate intracellular space was included in order to simplify the 
model. For systemic kinetics, a one compartment model is used. The dosing in the 
simulations was reproduced from the corresponding in vivo studies to enable 
comparison. For those studies where drug was administered subcutaneously, an 
additional compartment was used to describe the absorption of drug into the blood 
circulation. The structure of the model and the related equations are presented in 
Appendix 1.  
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Figure 2. Schematic representation of the pharmacokinetic model. 
 
The model makes several assumptions as it is a very simplified representation of the in 
vivo setting. It is assumed that p-glycoprotein is the only form of active transport at the 
BBB and that the in situ measured permeability in knockout mice (Kin,KO) equals the 
passive permeability component of transport. This passive diffusion is also set to be 
equal in both inward and outward directions. Drug is taken to distribute evenly into the 
brain tissue and not concentrate in intracellular fluids for example. For simplicity, as in 
previous  models  of  BBB  transport,  it  is  assumed  that  the  clearance  of  drug  via  the  
cerebrospinal fluid and drug metabolism in the brain is insignificant (Syvänen et al. 
2006). 
 
P-glycoprotein mediated efflux was the focus of the modeling, but because Michaelis-
Menten parameters values were unavailable, the incorporation of saturable active 
transport into the model was not possible. Instead, based on kinetic considerations 
discussed by Kalvass and Pollack (2007), the magnitude of efflux was defined using the 
in vivo efflux ratio (ER) determined in mice.  
 
The  equation  for  efflux  was  based  solely  on  the  definitions  of  ER,  Kp and  Kp,uu. 
Combining equations 2 and 3, we can state that: 
?? = ??? ???????? ???? × ?????????    (5) 
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According to the assumptions of the PK model, the clearance of compounds in 
knockout animals is mediated by passive diffusion only and it is equal to the in situ 
perfusion derived Kin value (Kin,KO). Kp in knockout animals is then defined by: 
??? ? = ???? ????? ? × ????????????????? = 1 × ?????????????????   (6) 
In wild-type animals, p-glycoprotein plays an additional role in the efflux of substrates 
and so the Kp,WT equation gets the form: 
??? ? = ???? ????? ?????? × ?????????????????   (7)  
where CLef is the p-glycoprotein mediated clearance that with passive permeability 
makes up the total outward clearance.  
 
Combining equations 4, 6 and 7 gives the final equation for efflux: 
???? ? ???? ? × (?? ? 1)   (8) 
A similar way modeling efflux with the ER has been used by Zhao et al. (2009a) on 
theoretical fexofenadine kinetic simulations.  
 
3.4 Physiological Parameters for Rat and Mouse 
 
The PK model was originally built with mouse physiological parameters, because the 
knockout data that plays an important role in the model in defining the BBB 
permeability and magnitude of efflux is derived from studies in mice. However due to 
the limited amount of in vivo concentration data available, both rat and mouse models 
are used in the simulations depending on the species that the brain concentration data 
was available for (Table 1).  
 
Table 1. Physiological parameters of mouse and rat used in the simulations  
 Mouse Rat 
Weight (g) 30 a 250 b 
Brain Weight (g)b 0.36 1.8 
Brain Volume (ml/kg) 13.4 c 4.8 a 
a) Kalvass et al. 2007a b)Davies and Morris 1993 c) Kalvass et al. 2007b  
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3.5 Compounds and Drug-Related Data Used in the Pharmacokinetic Model 
 
The drugs to be modeled and the parameters used were selected on the basis of the 
availability of data. Unfortunately it was difficult to find suitable compounds due to the 
need for many different parameters as well as brain concentration time course data, so 
only 3 compounds could be selected for the final model.  
 
The structure of the model was tested using diazepam, a well-characterized CNS drug 
with good permeability and which is thought to permeate the blood-brain barrier by 
passive diffusion (Dubey et al. 1989; Yamazaki et al. 2001; Doran et al. 2005; 
Summerfield et al. 2007). The uptake of diazepam is flow-limited and it is often used as 
a flow marker in the in situ brain perfusion method (Takasato et al. 1984). Because 
diazepam is uninfluenced by p-glycoprotein the active efflux was assigned to be zero in 
this simulation.  
 
Substrates of p-glycoprotein selected for simulations were morphine, loperamide and 
quinidine. Of these compounds morphine is a centrally acting analgesic and loperamide 
and quinidine are both non-CNS drugs that are classic p-glycoprotein substrates. 
Although the compound set is extremely small, there is some variety in the compound 
properties (Table 2). Morphine, despite being a CNS active drug, has low brain 
permeability in both p-glycoprotein knockout and wild type mice, unlike quinidine and 
loperamide, which have higher permeability in knockout mice (Dagenais et al. 2004; 
Zhao et al. 2009b). The minor effect of p-glycoprotein  on morphine brain disposition is 
also shown as low ER, but ER values of up to 39 and 64 have been reported for 
quinidine and loperamide, respectively (Kalvass et al. 2004; Uchida et al. 2011b). The 
ER values used in simulations were taken from a study by Doran et al. (2005), because 
these were calculated using AUC. The drug related data used in the simulations of all 
four drugs is reported in Table 3. 
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Table 2.  Properties of the p-glycoprotein substrate drugs used in simulations (European 
Bioinformatics Institute 2011) 
 Morphine Loperamide Quinidine 
Structure 
 
 
 
Class Base Neutral Base 
MW 285.3 477 324.4 
ACD LogD7.4 0.043 3.613 0.98 
HBA 4 3 4 
HBD 2 1 1 
Kin,WT mouse 
(ml/100g/min) 
1.04 a 9.86 a 3.4 b 
a) Dagenais et al. 2004 b) Zhao et al. 2009b 
 
Table 3. Drug related parameter values used in the simulations 
Drug CL 
(ml/min/kg) 
Vd (ml/kg) fu,plasma fu,brain Kin (KO) 
(ml/100g/min) 
ER 
 
ka# 
Diazepam 214.7 a  4500 a 0.11 b 4.54 b 197.3 c - - 
Morphine 95 d 2900 d 0.32 e 0.5 e 1.29 f  1.65 g 0.27 d 
Loperamide 58 d 32000d  0.023 h 0.0046h 103 f 9.3 g 0.063 d 
Quinidine 31.5 i 25800 i 0.265 k 0.0364k 40 m * 36 g *  - 
a) Klotz et al. 1976 b) Dubey et al. 1989 c) Summerfield et al. 2007 
d) Kalvass et al. 2007a e) Maurer et al. 2005 f) Dagenais et al. 2004  
g) Doran et al. 2005 h) Kalvass et al. 2007c i) Mansor et al. 1990 k) Liu et al. 2009  
m) Kusuhara et al. 1997  
# ka is the absorption coefficient after subcutaneous injection  
* Quinidine Kin is from a rat study using chemical inhibition of p-glycoprotein and the efflux 
ratio is from a knockout mice study, although the model is built for rat. 
  
3.6 Structure of the Theoretical In Vitro Model 
 
In addition to in vivo modeling, a theoretical model was built to study the robustness of 
a typical in vitro setup used to measure efflux ratios of drugs. The model was built to 
resemble a transcellular monolayer study where permeability is measured in both the 
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apical to basolateral and basolateral to apical directions (Figure 3). One active efflux 
transporter assumed to follow Michaelis-Menten kinetics was incorporated into the 
model. The initial concentration, well-plate size, sampling and experiment duration was 
chosen to mimic a possible real life in vitro experiment (Polli et al. 2001; Summerfield 
et al. 2007). The structure of the model and equations can be seen in Appendix 2. 
 
Figure 3. Schematic representation of the in vitro setup mimicked by the theoretical 
model. Api and Baso refer to the apical and basolateral compartments respectively. 
 
Papp values were calculated based on accumulated amount of drug in the receiver 
chamber over the simulation period (60 min) as if samples were taken at intervals of 10 
minutes (Equation 9). 
???? = ????? × ????    (9) 
where S is the area of the insert (1.12 cm2) and C0 is the initial concentration in the 
donor chamber and dQ/dt is calculated from a linear regression of cumulated amount of 
drug in the receiver chamber. ER was defined by equation (10): 
?? = ???????
???????
   (10) 
where PappB-A and PappA-B are the apparent permeabilities in basolateral to apical and 
apical to basolateral directions, respectively. 
 
The parameters varied in the simulations were passive permeability (Ppass), Vmax, Km and 
test concentration (C0) (Table 4). The concentration at the transporter binding site was 
taken to equal the concentration in the basolateral chamber. The range of passive 
permeability was estimated to be 0.1-100 *10-6 cm/s based on Papp values from MDR1-
MDCKII monolayer studies. The range was further limited based on preliminary 
simulations to maintain sink conditions (? 10 % of drug in the receiver chamber at the 
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end of the experiment) and make sure that permeability remained linear during the 
“sampling“ time to enable the determination of Papp using Equation 9. The maximal 
Vmax and minimal Km values were also restricted due to these considerations. 
 
Table 4. Range of parameter values in the in vitro simulations 
Parameter Ppass  
( 10-6 cm/s) 
Vmax a 
??mol/min) 
Kmb 
 (?M) 
Concentration  
??M) 
Range 0.1 – 10 0.001 - 0.1 10, 50, 100 and 500 1 and 10 
a) based on values used by Mahar Doan and Boje (2000) who estimated the range from 
published data on large neutral L-amino acid transporters from in situ perfusion studies. 
b) based on Km values reported for p-glycoprotein in the transporter database (TP-
Search 2011) 
 
 
4 RESULTS 
 
4.1 Interspecies differences 
 
Interspecies differences in Kin and fubrain were studied for mice and rats (APPENDIX 4). 
The fraction of unbound drug in the brain determined from brain homogenates seems to 
correlate rather well for the set of 19 compounds (R2 = 0.80). 74 % of compounds had 
fu,brain values below 0.2. For in situ perfusion, the correlation between Kin values from 
rat and mouse was 0.66 (n=9). Although the compound set was very limited, 
compounds  were  fairly  well  spread  out  over  the  range  of  Kin  values.  In  this  set,  Kin 
values measured in mice tended to be slightly higher than those in rats. 
 
4.2  Variability of In Vitro ER Values and Correlation with In Vivo ER  
 
To consider the variability of ER values measured in monolayer studies, results from 
three studies were compared. The studies used a similar protocol with differing test 
concentrations.  Correlation  in  two  studies  using  concentrations  of  10-20  ?M  seems  
excellent (R2 = 0.99, n = 15), but it should be noted that it is distorted by a single high 
ER value as most of the data is situated at the low end and all of these compounds lie 
below the  trend  line  (APPENDIX 4).  Correlation  between the  10  ?M study of  Mahar  
Doan et al. (2005) and a study by Summerfield et al. (2007) using 3 ?M concentrations 
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was poorer (R2 = 0.44, n = 15). The in vitro ER values from both the 3 ?M and the 10-
20  ?M studies  were  also  compared  separately  with  in  vivo  measured  ER.  In  vivo  ER 
correlated much better (R2 = 0.67, n = 18) with the lower concentration in vitro data 
than the higher concentration data (R2 = 0.08, n = 21).  
 
4.3 Differences in reported ER Values for Quinidine and Loperamide  
 
Because loperamide and quinidine are well-known substrates of p-glycoprotein, various 
estimates of in vivo efflux ratio can be found in literature (Table 5). In vitro estimations 
of  ER values  in  MDR1-transfected  MDCKII  cell  systems have  also  been  reported  for  
these two drugs. Values of 7.8 and 9.9 are quoted for loperamide and 11.4 and 27.2 for 
quinidine, which are in the same range as the in vivo values (Polli et al. 2001; Mahar 
Doan et al. 2002; Carrara et al.2007). In comparison 10 times larger values, 237 and 338 
for loperamide and quinidine respectively, were reported in a study by Wang et al. 
(2005) in MDR-MDCK cells. A single in vitro ER value (1.7) was found for morphine 
and it was identical to the in vivo ER (Doran et al. 2005; Feng et al. 2008). 
 
Table 5. Efflux ratio (ER) values from knockout/wild type mouse studies reported in the 
literature. 
Drug Reported 
ER value 
Knockout 
mouse type 
Dose and Method of Determination of 
ER 
Reference 
Quinidine 36 FVB 
mdr1a/1b  
10 mg/kg s.c., 4 samples 0-5 h from 
dosing, calculation based on AUC  
Doran et al. 
2005 
8.29 mdr1a  50 mg/kg [3H]quinidine i.v., single 
time-point at 4 h after dosing 
Fromm et al. 
1999 
39.4 FVB 
mdr1a/1b  
692 nmol/min bolus + 838 nmol/kg/h 
100 min infusion, single time-point at 
100 min 
Uchida et al. 
2011b 
Loperamide 9.3 FVB 
mdr1a/1b 
1 mg/kg s.c, 4 samples 0-5 h from 
dosing, calculation based on AUC 
Doran et 
al.2005 
6.7 FVB mdr1a 1 mg/kg [3H] loperamide oral injection, 
reported ER for single time-point at 4 h 
after dosing  
Schinkel et 
al. 1996 
64 CF-1 mdr1a 2 mg/kg s.c., single time-point at 4 h Kalvass et al. 
2004 
31.4 FVB 
mdr1a/1b  
201 nmol/min bolus + 262 nmol/kg/h 
100 min infusion, single time-point at 
100 min 
Uchida et al. 
2011b 
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4.4 Model Structure Validation with Diazepam 
 
The model was able to simulate the concentration-time profile diazepam in the brain 
and blood reasonably well (APPENDIX 5). The Kp value is identical to the one stated in 
the original study by Dubey et al (1989). Concentration levels in the brain and blood are 
different from those in the publication, which is due to differences in systemic kinetic 
parameters. Because diazepam, being a passively distributing drug, was not the focus of 
the study, this difference in systemic kinetics was overlooked and it was concluded that 
the model structure is sound based on profile shape and correct Kp simulation. 
 
4.5 Modeling Brain Distribution of P-glycoprotein Substrate Drugs 
 
For all three compounds, the single central compartment in the model was able to fairly 
well describe the systemic kinetics (Figure 4, 5 and 6). The success of the model in 
capturing brain concentrations was variable. For morphine, two studies were available 
for comparison and in both of these the concentration level in the brain and shape of 
concentration curves was similar to the publication, but time (Tmax) to reach maximum 
concentration in the brain (Cmax) was longer in the simulations: 57 min in both 
simulations versus ? 20 min in the Kalvass et al. (2007a) and ? 25 min in Andersen et 
al. (2009) (Figure 4 and 5). Reported Cmax for Andersen et al. (2009) was 0.11 nmol/g 
and the corresponding simulation Cmax was 0.13 nmol/g.  
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Figure 4. Total plasma and brain concentrations of morphine in mice as a function of 
time after 3.6 mg/kg s.c. dose predicted by the model (A) and reported by Kalvass et al. 
2007a (B). In figure 4B, the black circles and triangles denote the plasma and brain 
concentrations respectively. Open diamonds denote the antinociception (not the focus of 
the current study). 
 
Figure 5. Total blood and brain concentrations of morphine in mice as a function of 
time after 5 ?mol/kg s.c. dose predicted by the model (A) and reported by Andersen et 
al. 2009 for blood (B) and brain (C) 
 
The brain concentration – time profile of loperamide was simulated correctly, but there 
was great overestimation in the concentration level as shown by Cmax: 797 ng/g 
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compared to roughly 100 ng/g estimated from the publication figure (Kalvass et al. 
2007a) (Figure 6). As with loperamide, the profile of quinidine (unbound) brain 
concentrations was simulated correctly, but in this case, there was underestimation in 
both the plasma and brain concentrations (Figure 7). At six hours after the beginning of 
the infusion the total quinidine concentration in the brain was 938 ng/g in the study, 
whereas the simulations predicted it to be 245 ng/g (Liu et al. 2009). As the plasma 
concentration  was  also  lower  in  the  simulation  than  in  the  study,  Kp at 6 h was 
compared. The simulated Kp (6h) was 0.135 whereas it was 0.36 in the original study. 
 
 
Figure 6. Total plasma and brain concentrations of loperamide in mice as a function of 
time after 3.6 mg/kg s.c. dose predicted by the model (A) and published by Kalvass et 
al. 2007a (B). In figure B, the black circles and triangles denote the plasma and brain 
concentrations respectively. Open diamonds denote the antinociception (not the focus of 
the current study). 
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Figure 7. Unbound plasma and brain concentrations of quinidine in rats as a function of 
time after 5 mg/kg bolus dose and 9 mg/kg/h continuous infusion predicted by the 
model (A) and reported by Liu et al. 2009 (B). In figure B, the solid and open circles 
denote the plasma and brain concentrations respectively.  
 
4.6 Theoretical In Vitro Model 
 
In the concentration range chosen (concentration << Km), concentration had no effect on 
the  ER  values  as  expected.  In  additional  simulations  (at  Km 10 ?M) to test possible 
saturation of transport, even a concentration of 1000 ?M resulted in a minimal decrease 
in ER (data not shown). The ER was equal for all situations with the same passive 
permeability and Vmax/Km ratio which is also in line with kinetic considerations, ie. 
when concentration is much lower than Km,  the  “clearance”  is  governed  by  Vmax/Km. 
The  larger  the  ratio  is,  the  more  effective  the  efflux  is.  The  highest  Vmax/Km in the 
simulations  was  2  ml/min  as  more  efficient  efflux  was  ruled  out  to  maintain  sink  
conditions.   
 
The simulation shows that ER is governed together by Ppass and  Vmax (or  Vmax/Km). 
Passive permeability has a clear influence on the simulated ER values (Figure 8 and 
Table 6). By visual inspection, significant efflux is apparent only at Ppass values below 
2.5 *10-6 cm/s in the simulation range. The effect of Vmax is clearly shown in Figure 8 at 
low passive permeability. The highest ER achieved in the system was 299. At the 
lowest permeabilities the doubling of Vmax/Km, either by an increase in Vmax or decrease 
in  Km, lead to nearly two-fold ER values. The sensitivity to changes in Vmax/Km 
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decreased greatly along with the increase in Ppass. The increase in ER on doubling 
Vmax/Km at permeability 10*10-6 cm/s was only 1.6-fold (from 2.5 to 4) for the highest 
Vmax/Km in the simulations and even smaller changes (roughly 1.2 fold) with weaker 
efflux.  
 
Figure 8. The effect of passive permeability (Ppass) and maximum transport velocity 
(Vmax) on the efflux ratio (ER) as simulated with the in vitro model when Km = 50 ?M 
and concentration 1 ?M. Other simulations gave similar results. In figure 8A single 
calculated ER values are shown and colors are used only to better distinguish adjacent 
Vmax data series in the figure and have no other meaning. Figure 8B shows the effect of 
Vmax and Ppass as a continuous surface where color marks the value of ER. 
 
Table 6. Effect of Ppass on the ER value in Vmax/Km range of 0.002 – 2 ml/min. 
Ppass (* 10-6 cm/s) ER range 
0.1 1–299  
1 1–31 
10 1–4 
 
 
5 DISCUSSION 
 
5.1 Correlations 
 
Murakami et al. (2000) reported a good correlation (R2 = 0.898) between PS values in 
mice and rats determined with in situ perfusion (n = 21). The slightly weaker correlation 
(R2 = 0.66) observed here may be attributed to the small number of compounds and 
minor differences between study protocols in the mouse and rat studies in addition to 
the fact that the Kin values  used  in  the  comparison  were  not  corrected  for  flow.  The  
good correlation between rat and mouse fu,brain values is in line with a previous study 
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that reported good correlation between mouse and rat brain tissue binding (R2 = 0.9887, 
n = 25) (Wan et al. 2007). The correlation may not be unique to these two species, as 
correlations of above 0.9 were reported for a group of 21 compounds when comparing 
any two of human, landrace pig and rat fu,brain values (Summerfield et al. 2008).  
 
One of the advantages of the presented PK model is that the structure allows it to be 
easily applied to different species. The mixing of data from species in a single 
simulation should be regarded with caution, but the good correlation between Kin and 
fu,brain values in mice and rats justifies the use of mouse data in the quinidine model. The 
SDZ PSC 833 inhibited brain uptake of quinidine in rats was only slightly lower than 
that in knockout mice (40 vs. 54.1 ml/100g/min), although it is not possible to say 
whether full inhibition was achieved (Kusuhara et al. 1997; Zhao et al. 2009b). The 
failure of the model to correctly predict quinidine concentrations in the brain could 
therefore be due to interspecies variability, but is also likely to be greatly affected by 
experimental conditions in the determination of the ER. 
 
The surprisingly low correlation between the two transcellular monolayer studies with 
different concentration levels could be an indication of low Km-values for some 
compounds resulting in saturation with concentrations above 10 ?M. An overview of in 
vitro  Km values in the TP-search Transporter database (2011) also suggests values as 
low as 0.1 ?M for p-glycoprotein. The interpretation that saturation is one of the reasons 
for the poor correlation is also supported by the significantly better in vitro – in vivo 
correlation with low concentration compared to higher concentration in vitro ER.  
 
Other experimental factors could also explain part of the variability. Only the study by 
Summerfield et al. (2007) used colchicine to maintain p-glycoprotein expression, 
whereas the other studies with higher concentrations used no selection agent. 
Differences in sampling could affect results. Sampling procedures were not reported in 
the publications of Polli et al. (2001) and Mahar Doan et al. (2002), but Summerfield et 
al. (2007) reported only single time-point sampling at 60 min. This could result in 
biased results, if linear conditions of uptake are not maintained. In addition to this, 
Summerfield et al. (2007) carried out the experiments 8 days after seeding and TEER 
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was very high (1800-2000 ?*cm2), whereas the other two experiments were done after 
3 days, so passive permeability could be higher. This and colchicines selection could 
explain the tendency for higher ER reported by Summerfield et al. (2007) compared to 
Mahar Doan et al. (2002). 
 
The correlation of in vitro and in vivo ER values has been studied previously (Adachi et 
al. 2001; Yamazaki et al. 2001, Chen et al. 2003). Yamazaki et al. (2001) reported an 
excellent correlation (R2 = 0.92) for 7 compounds in LLC-mdr1a cells with in vivo 
mouse  ER,  but  lower  correlation  with  LLC-MDR1  cells  (R2 = 0.53). This is an 
indication that in vivo – in vitro correlation (IVIVC) could suffer if parent cells are 
transfected with human MDR1, but results are compared with mouse in vivo data 
adding a component of interspecies differences. However, good correlation with mouse 
ER (R > 0.8) was achieved in both Caco-2 and LLC-MDR1 cell lines for 10 drugs 
(Adachi et al. 2001). A correlation of 0.67 for the low concentration in vitro ER (using 
MDR1-MDCKII) and in vivo ER was also noted in the current study. With regard to the 
significance of in vitro test concentration, it should be noted that both the above studies 
also used low concentrations (? 1 ?M) (Adachi et al. 2001; Yamazaki et al. 2001). 
Although compound concentration and mismatch of transfected transporter and in vivo 
species are likely to influence the correlation, a literature based study comparing mouse 
in vivo ER and in vitro ER values in MDR1 transfected cells from a diverse set of 
studies found a good correlation of 0.79 (Chen et al. 2003). 
 
It should be noted that 77 % and 65 % of the 26 compounds used in the current in vitro 
– in vivo comparison had ER values below 2 in vivo and in vitro, respectively. An ER 
of 2 has been suggested as a cutoff for classifying compounds as p-glycoprotein 
substrates (Polli et al. 2001). Therefore, even though the correlation of the ER values as 
a whole is not excellent, the classification is correct and such minor differences are 
unlikely to have a vast effect on predictions, although input data in model should be as 
accurately determined as possible. As is seen in Table 5, variation in the in vivo 
measured ER values is also great, for example up to ten-fold differences were noted for 
loperamide.  
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5.2 Structure and Assumptions of the Pharmacokinetic Model 
 
The model assumptions are one of the possible sources of error in predictions. The 
model assumes that data generated in p-glycoprotein knockout mice differs from wild 
type mice with regards to p-glycoprotein function only, but upregulation of breast 
cancer resistance protein (bcrp) and mdr1b has been reported in mdr1a (-/-) mice 
(Schinkel et al. 1994; Cisternino et al. 2004a). It is therefore possible that upregulation 
also exists for some transporter(s) in the mdr1a/b double knockout mice used in the in 
vivo ER studies although this has not been elucidated.  
 
The approximation that p-glycoprotein is the only transporter affecting permeability and 
that the Kin,KO equals the passive permeability, is also crude as the range of transporters 
expressed at the BBB is large (Kamiie et al. 2008; Shawahna et al. 2011). In addition to 
p-glycoprotein, morphine has been suggested to be a substrate of probenecid sensitive 
transporters at the BBB and in the brain (Tunblad et al. 2003; Bourasset and 
Scherrmann 2006). Transport of loperamide by transporters besides p-glycoprotein at 
the  BBB  is  unknown  and  it  has  been  classified  as  a  non-substrate  of  human  BCRP  
(Tournier et al. 2011). Quinidine is proposed to be a substrate of the rat organic cation 
transporter 1 (rOCT1), but this is unlikely to affect BBB permeability as OCT1 
expression at the BBB has been too low for quantification at least in human brain 
microvessel samples (Busch et al. 1996; Uchida et al. 2011a).  
 
The assumption that drug is distributed evenly in the brain and does not concentrate in 
cells can also be misleading. Drug transporters are expressed in the brain parenchyma as 
well  as  at  the  BBB  and  can  thus  affect  distribution  within  the  brain  (Dauchy  et  al.  
2008). For example accumulation of morphine in brain cells due to active transporters 
was suggested in a microdialysis study in rats (Bourasset and Scherrmann 2006). 
Uneven distribution in the brain could also arise from regional differences in blood flow 
in the brain, which can influence the distribution of flow-limited compounds (Zhao and 
Pollack 2009b). Transporter expression may also exhibit regional differences. 
 
Liu et al. (2005) concluded that for drugs having permeability limited uptake into the 
brain (i.e. uptake values lower than cerebral blood flow), blood flow could be 
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eliminated from the brain PK model for simplification. The same principle was applied 
here because all three model compounds were taken to be permeability limited as 
loperamide was the only compound even remotely likely to be influenced in a 
significant way by flow in knockout mice. Uptake of diazepam (used for model 
validation) is flow limited, so its uptake is likely to correspond to blood flow. The Kin 
value (214.7 ml/100g/min) used for diazepam is in accordance with reported cerebral 
blood flow for rat measured with MRI (233 ml/100g/min) although the result could be 
affected by anesthesia as lower values have been reported (Davies and Morris 1993; 
Thomas et al. 2006). If in fact blood flow in the mouse brain is close to the permeability 
of loperamide, the incorporation of cerebral blood flow into the model should be 
considered, but the importance of this is unknown as variable estimations of cerebral 
blood flow exist. 
 
Achieving correct plasma kinetics is the first step to correct brain concentrations as the 
plasma concentration is the driving force for brain kinetics. The estimates found in 
literature  for  the  systemic  parameters  clearance  (CL)  and  volume  of  distribution  (Vd) 
were varied. Therefore it was difficult to simulate a plasma concentration curve that 
corresponds with the publications for diazepam and quinidine, because systemic kinetic 
parameters were not defined in the publications, unlike for loperamide and morphine. 
Watari et al. (1989) suggested a 2 compartment model to capture quinidine plasma 
kinetics alongside dose-dependent clearance, both of which could explain problems in 
describing plasma kinetics with the current model. Disagreement of systemic kinetic 
parameters could arise from inter-individual variability of animals, experimental 
procedures or data handling to calculate parameter values.  
 
The addition of a compartment for the brain microvessel intracellular space would make 
the model resemble the in vivo situation better, but was left out of the model to simplify 
the model. With regard to the transport mechanism in the model structure, p-
glycoprotein is included as an efflux pumping out drug that has entered the brain. It has 
however been postulated that p-glycoprotein acts through hindering influx by picking 
up substrates as soon as they enter the endothelial cell membrane (Stein et al. 1994).  
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The integration of p-glycoprotein as an influx hindrance mechanism would have 
increased the efficiency of p-glycoprotein to hinder the permeation of drugs (Syvänen et 
al. 2006). It is difficult to say whether the choice of definition of p-glycoprotein as an 
efflux and not an influx hindrance or the exclusion of BBB intracellular space is a 
significant reason for the failure of predictions. As hindsight, the difference (roughly 
10-fold) in Kin values for quinidine and loperamide measured in knockout and wild type 
mice supports the mechanism of influx hindrance. However, while this mechanism may 
have improved predictions for loperamide, which was overpredicted by the model, it 
would  have  done  the  opposite  for  quinidine  brain  concentrations,  which  were  already  
underpredicted.  It is also possible that the mechanism of action of p-glycoprotein 
depends on the substrate, which further complicates the choice of mechanism for a 
generic model (Stein et al. 1994).  
 
Another aspect which is overlooked in the model is the possible saturation of transport. 
Adachi et al. (2001) reported Km values determined in ATP hydrolysis experiments in 
membrane fractions of 13.8 ?M and 5.42 ?M for loperamide and quinidine respectively. 
The corresponding values published by Feng et al. (2008) were 11.4 and 13.7 ?M. In 
the simulations the maximal brain unbound concentration of loperamide was 0.007 ?M 
and 0.18 ?M of quinidine. Even though the Km measured with ATP hydrolysis may not 
present the definitive value of Km as it is an indirect measure of transport, this result 
suggests that saturation of transport is not an issue in the model for quinidine and 
loperamide. Morphine saturation is also highly unlikely as saturation of transport in in 
situ brain perfusion in mice failed in the concentration range of 3 nM – 2 mM 
(Cisternino et al. 2004b).   
 
5.3 PK Model Data and Parameters 
 
In a simplified system where only one transporter is considered to affect distribution, 
Kp can be calculated from (Uchida et al. 2011b): 
?? = ??????????????? × ???    (11) 
As shown by Equation 11 the fu and the ER play a major role on the Kp ratio simulated 
by the model, which means that certainty in the determination of these parameters is 
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important. Nevertheless, the determination of these parameters is not always 
unambiguous as there are several factors affecting results.  
 
The unbound fraction in brain and plasma can be determined with equilibrium dialysis 
from plasma samples and brain homogenates (Kalvass and Maurer 2002). Although the 
procedure is fairly straightforward, some deviation from real life could arise from 
experimental factors like new binding sites being exposed during homogenization or 
unspecific binding to the study apparatus for lipophilic drugs (Becker and Liu 2006). 
Two pairs of fraction unbound values were available for morphine: 0.32 and 0.5 for 
fu,plasma and  fu,brain respectively by Maurer et al. (2005) and interestingly inverse values 
of 0.5 and 0.41 by Kalvass et al. (2007c). The only clear difference in the two 
experiments was drug concentration which was 1000 ng/g (? 3.5 nmol/g) and 1 ?M in 
Maurer et al. (2005) and Kalvass et al. (2007c) respectively, but otherwise a similar 
protocol was followed.   
 
The values reported by Maurer et al. (2005) were chosen for the model simulations 
because this fu,plasma/fu,brain ratio coincided better with the Kp determined in knockout 
mice, assuming that morphine permeability in these mice is governed only by passive 
diffusion (Doran et al. 2005). The use of fu-values reported by Kalvass et al. (2007c) in 
the morphine simulations would have resulted in roughly 1.7-fold higher Cmax in the 
brain, but had next to no effect on Tmax and on plasma concentrations (data not shown).  
 
For permeability data in the model, no transformation from Kin to  PS (flow corrected  
permeability) was made, as it was not reported in all the original publications and has 
minor effect on permeability limited compounds. The PS value for loperamide, would 
be roughly 20 % higher than the Kin,KO (103 ml/100g/min),  according to the Crone-
Renkin equation if perfusate flow is estimated to be 255 ml/100g/min (Takasato et al. 
1984; Dagenais et al. 2004). The use of this PS value only minimally increases brain 
concentrations of loperamide in simulations, resulting in an increase in Cmax from 797 to 
813 ng/g and decrease in Tmax from 105 to 93 min (data not shown).  
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There is clear variation in the reported ER values which can be due to several different 
reasons (Table 5). When defining Kp and subsequent ER values, it is important to make 
sure that no residual blood is present in the brain during analysis or that the residual 
amount of drug remaining in the vascular space is subtracted in calculations (Friden et 
al. 2010). Without correction, Kp values can be underestimated, especially for poorly 
permeating compounds. The ER values that were used in the model were chosen on the 
basis that they were calculated from AUC0-4h, as other reported values were based on 
single time point estimates. Single time point estimates represent the correct Kp only in 
steady-state infusion or during the elimination phase if elimination from the brain is 
faster than that from plasma (Hammarlund-Udenaes et al. 1997). Even the AUC-derived 
value has its drawbacks as data is not gained for a single animal, but pieced together 
from single time point samples of different animals (Doran et al 2005). The mouse 
strain used in the study could also affect the results if expression of other transporters is 
altered.  
 
The dose level selected for Kp evaluation can additionally affect results as high dosing 
could in theory result in saturation of transport and an underestimation of Kp and ER. 
The dosing of loperamide and quinidine are however similar between in vivo ER studies 
and for loperamide a larger dose resulted in a higher ER and therefore other factors are 
likely to explain the differences (Table 5). It should be noted that the dose used in the in 
vivo brain concentration study of Kalvass et al. (2007a) (50 mg/kg s.c.) was much 
higher than that used in the ER evaluation (1 mg/kg s.c.) which could affect results. 
Despite this the model gave an overestimation of brain concentrations, which is not an 
indication of saturation with larger doses. Cu,brain (6h) for quinidine was 4.7-fold higher 
with the lowest reported ER (8.29) than with the highest (39.4) (data not shown). With 
loperamide, ER had a clear effect on Cmax and Tmax, ranging from 122.6 ng/g at 62 min 
to 1069 ng/g at 124 min with the highest reported ER (64) and the lowest ER (6.7) 
respectively.  
 
5.4 Theoretical In Vitro Simulations  
 
The  range  of  Vmax,  Km and  Ppass values  chosen  for  the  simulations  was  based  on  
literature reports. Defining a suitable range for the Km and  Vmax values was difficult, 
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because a variety of values are cited in the literature depending on the determination 
method.  A  Km range of 9.4 to 441 ?M (CNS drugs) and 1.4 to 291 (non-CNS drugs) 
reported by Feng et al. (2008) in ATPase hydrolysis experiments coincides fairly well 
with the simulation range. Vmax values measured in MDR1-MDCKII are scarce and that 
is why they were not used to determine the range. Some values have however been 
reported at 145 pmol/min/cm2 (Tang et al. 2002), 0.2 ?mol/min/cm2 (Soldner et al. 
2000), 13.25 pmol/min/cm2 and 1.26 pmol/min/cm2 (Shirasaka et al. 2008). This shows 
that the existence of lower Km and Vmax values than those used in the simulations cannot 
be ruled out, but lower values were not considered due to the risk of saturation or loss of 
sink conditions.   
 
Because the ER is dependent on the Vmax/Km ratio and not solely on either parameter,  
the used range can be regarded adequate as it covers Vmax/Km of 0.0002 - 2 ml/min. 
Figure 8 clearly shows that a relevant range was achieved and even in this simulation 
setting, ER values as high as 299 were reached. Adachi et al. (2001) for example 
reported Vmax/Km values between 0.2 and 31 ml/min/mg protein, but direct comparison 
is not possible as simulation values apply to the whole insert and not mg of protein. It 
should also be noted that the calculated Km and Vmax values are dependent on the 
measured concentration that is taken to equal binding site concentration. Here, efflux 
was related to basolateral concentrations, but it would be interesting to repeat 
simulations and relate it to the apical concentration and also to improve the model with 
an intracellular compartment. 
 
As demonstrated by the simulations, the ER value cannot be used to make predictions of 
saturability because Km = 100 and Vmax = 1, will give the same ER as Km = 1 and Vmax 
= 0.001, for example as they have the same Vmax/Km ratio.   Therefore the Km must be 
separately determined and compared with drug concentration to evaluate the possibility 
of saturation. Saturation did not, however, seem to be a problem in the simulations as 
1000 ?M concentration had minimal effect in simulations where Km was 10 ?M, but 
could become an issue with lower Km values. 
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The  Ppass range is based on uninhibited apparent permeability values in the apical to 
basolateral direction (PappA-B) in MDR1-MDCKII cells. This is likely to represent 
passive permeability as efflux is thought mainly to affect transport in the opposing 
direction. Also after incubation of the same cell line with 2 ?M elacridar, a p-
glycoprotein inhibitor, Summerfield et al. (2007) reported PappA-B values of 0.4 – 
54.7*10-6 cm/s and Mahar Doan et al. (2002) showed a remarkable change in PappA-B 
after this inhibition only for a small group of compounds.  
 
The  original  range  of  Ppass and  also  Vmax values had to be narrowed down greatly to 
achieve conditions where the simulated system would remain at sink conditions and the 
permeability in the linear range. Compounds that are highly effluxed or have high 
passive  permeability  require  a  shorter  duration  of  the  experiment  to  meet  these  
requirements. This underlines the fact that these assays are not universal and that care 
should be taken in designing these experiments when measuring large compound sets. 
This also shows the usefulness of simulations in designing experiments.  
 
This theoretical simulation demonstrates that current blood-brain barrier models are far 
from  being  tight  enough  to  be  used  for  ER  determination.  For  example  in  the  human  
immortalized BBB cell line hCMEC/d3, Papp for propranol was 75 *10-6 cm/s whereas 
values of 40.4 *10-6 cm/s and 46.9 *10-6 cm/s have been measured in the MDR1-
MDCKII cell line (Polli et al. 2001; Mahar Doan et al. 2002; Poller et al. 2008). This 
nearly two-fold difference is likely to be much greater for more hydrophilic compounds 
that rely more on the paracellular route. According to the simulations, overestimation in 
passive permeability is likely to affect ER measurements and the significance of efflux 
will be underestimated in current BBB cell lines. The simulation does not rule out the 
possibility of significant efflux arising at higher passive permeability, but it indicates 
that  this  would  require  a  more  efficient  efflux  (ie.  higher  Vmax and/or  lower  Km) than 
that  in  the  simulations.  However,  even  in  this  range  of  Vmax/Km covering 3 orders of 
magnitude,  ER  was  consistently  low  with  the  highest  Ppass (10 *10-6 cm/s) (Table 6). 
The likelihood of higher Vmax/Km ratios is difficult to evaluate because data concerning 
the Michaelis-Menten kinetics of p-glycoprotein is not yet fully elucidated. 
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5.5 Future Perspectives 
 
There is an interest in using in vitro techniques to replace animal experiments and 
increase throughput. For the proposed BBB PK model, two parameters could potentially 
be evaluated in vitro, the Kin and  ER,  but  currently  the  determination  of  ER  is  more  
realistic due to the problems regarding permeability in cell models of the BBB 
(Gumbleton and Audus 2001). The in vivo ER could theoretically be directly replaced 
with in vitro values, because even though the determination method is different, the 
efflux clearance (CLef) is defined in the same way in both cases.  
 
Taking into account all the factors discussed above, the use of in vitro derived ER in 
place of in vivo ER seems plausible. Fair IVIVC has been reported as discussed in 
section  5.1.  The  simulations  show  that  problems  may  arise  only  for  the  very  low  
permeability and/or highly effluxed compounds, but for others differences due to 
protein expression may be modest. Although the highest ER in the simulation was 299, 
in vivo ER values rarely surpass 50, so this may not be a problem. What is also evident 
is  that  the  use  of  in  vitro  ER  values  requires  a  cell  line  that  has  passive  permeability  
properties of the BBB. Care should also be taken in designing experiments with respect 
to experimental conditions and also choice of transfected protein versus in vivo species.  
 
Even in studies where good correlation is found between in vitro and in vivo ER values, 
there is often deviation of the slope of the correlation trend line from the line of unity. 
The same was noted in this study as slopes of 0.19 and 0.28 were calculated for the high 
and low concentration in vitro ER respectively, versus in vivo ER. Difference in p-
glycoprotein expression level was suggested to be the reason for this type of deviation 
by Adachi et al. (2001). As discussed in section 1.2, transporter expression is regarded 
as a noteworthy source of variability in ER and proteomics has already been employed 
to correct in vitro ER with reasonable success (Uchida et al. 2011b). The correction 
factor in the study by Uchida et al. (2011b) was however surprisingly low (0.92) as 
there was only minor difference between p-glycoprotein amount at the mouse BBB and 
the cell line. According to the simulations, differences in passive permeability are 
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perhaps  more  likely  to  distort  in  vitro  ER  values  than  minor  differences  in  p-
glycoprotein expression.  
 
The PK model presented in this study highlights some of the problems with using data 
commonly measured in brain distribution studies. It shows that this type of modeling 
approach is highly likely to fail due to the variability in data and complexity of different 
processes. The model would perhaps be more successful if the data was generated 
specifically for modeling, so that all the factors discussed above could be taken into 
consideration. At this point in the development of the model, the main problem seems to 
the reliability of data and interspecies differences seem minor, although this issue 
should also be addressed in the future.  
 
An advantage of this type of modeling, especially using the STELLA™ software, is that 
the model can easily be refined and new parameters integrated into the structure. It can 
be used for different species if physiological parameters are chosen accordingly, 
although it may be difficult to obtain some of the data such as the passive permeability 
(Kin,KO) in species where knockout relies on chemical inhibitors. The prediction of 
human  brain  permeation  with  the  model  is  the  ultimate  goal,  but  the  rodent  model  is  
also useful, as many preclinical studies are conducted with mice or rats. For now, rather 
than add new parameters or apply the model to a different species, it would be 
interesting to test the model on more compounds to get a broader picture of its 
predictive abilities and main source of weakness. After this, the next step is to replace 
the ER in the model with Michaelis-Menten kinetics to achieve a saturable model of 
efflux, but this requires further development of in vitro methods.  
 
 
6 CONCLUSIONS 
 
The focus of the study was to model p-glycoprotein substrate permeation into the brain 
using in vivo measured aspects of brain distribution and to evaluate the possibility of 
replacing in vivo data with in vitro values. The presented PK model was able to 
estimate morphine brain concentrations, but under- and overestimated the brain 
concentrations for quinidine and loperamide respectively. This failure could be due to 
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the ER value, which was used to define efflux, but for which highly variable in vivo 
measured values have been reported. Comparison of in vitro measured ER from 
different studies showed that experimental factors, such as test concentration, could 
affect correlation and should be considered carefully. In vitro derived ER with 
concentration of 3 ?M had good correlation with in vivo ER, which supports the 
possibility of using transcellular monolayer experiments to replace in vivo ER. A 
simulation of such an in vitro setup illustrated the importance of appropriate cell layer 
tightness in cell models, as the effect of efflux was highly dependent on passive 
permeability. Species differences in rats and mice for Kin and  fu,brain were moderate in 
comparison to the variability of ER. Altogether, this study was able to highlight some of 
the problems regarding PK BBB modeling and data generation. However, validation of 
the PK model with more compounds is needed to make further conclusions and both the 
PK and in vitro models could be refined by incorporating an intracellular space. 
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APPENDIX 1 
Structure of the PK BBB Model and the Related Equations 
 
W refers to the weight of the animal  
Wbr and Vbr refer to the physiological brain weight and volume respectively. 
 
Equations: 
Brain(t) = Brain(t - dt) + (FluxIN - FluxOUT - CLeflux) * dt 
Plasma(t) = Plasma(t - dt) + (Drug + FluxOUT + CLeflux - Elimination - FluxIN) * dt 
 
FluxIN = IF (Cup>Cubr) THEN ((Cup-Cubr)*Kin_KO) ELSE 0 
FluxOUT = IF (Cubr>Cup) THEN ((Cubr-Cup)*Kin_KO) ELSE 0 
CLeflux = Cubr*((ER-1)*Kin_KO) 
Elimination = CLsys*Cp 
 
Cbr = Brain/Vbr 
Cp = Plasma/Vd 
Cubr = Cbr*fubr 
Cup = Cp*fup 
 
 
 
APPENDIX 2 
Structure of the In Vitro Model and the Related Equations 
 
Equations: 
Api(t) = Api(t - dt) + (FluxOUT + EfFlux - FluxIN) * dt 
Baso(t) = Baso(t - dt) + (FluxIN - FluxOUT - EfFlux) * dt 
 
FluxIN = IF (Capi>Cbaso) THEN (Capi-Cbaso)*PS ELSE 0 
FluxOUT = IF Cbaso>Capi THEN (Cbaso-Capi)*PS ELSE 0 
EfFlux = Vmax*Cbaso/(Km+Cbaso) 
 
Capi = Api/Vapi 
Cbaso = Baso/Vbaso 
PS = Ppass*S 
 
  
 
 
APPENDIX 3  
 
Drug Data used for Correlation Studies 
 
Drug 
MDR1-MDCKII Mouse Rat 
 
ER  fu,brain 
Kin 
(ml/100g/min) 
ER fu,brain 
Kin  
(ml/100g/min) 
(Ref) a) b) c) d) e) f) a) a) 
Amantadine 0.8 0.95 0.84 
 
  0.233 
 
Amitriptyline 1.9 1.34  
 
335  0.009 321 
Amprenavir 
 
29.0 32.4 
 
  
  
Buspirone 
 
0.95  
 
  
  
Carbamazepine 0.8 0.98  0.116 173 1.1 0.1185 96 
Chlorpheniramine 
 
0.93 1.14 
 
  
  
Chlorpromazine 0.8 1.27 1.09 0.00076 300 1.3 0.0021 261 
Cimetidine 
 
4.77 2.19 
 
  
  
Citalopram 20.1   0.0306  1.9 0.0490 
 
Clozapine 1.3   0.0094 118 1.6 0.11 226 
Colchicine 
 
 11.34 
 
1.7  g)  
 
1.4 
Cyclobenzaprine 
 
0.97  
 
 1.4 
  
Diazepam 1.0   0.050 250  h) 1.2 0.036 197 
Diltiazem 
 
1.53 1.64 
 
  
  
Doxepin 1.9 1.15  
 
  0.0250 
 
Ethosuximide 0.8   
 
 1 
  
Fluoxetine 1.2 1.18  0.0023  1.5 0.004 
 
Fluvoxamine 
 
1.2  
 
 2.3 
  
Gabapentin 0.8   
 
15  0.782 16 
Haloperidol 1.3 1.04  0.0071  1.4 0.011 
 
Lamotrigine 1.6   
 
 1 
  
Lidocaine 
 
0.83 0.99 
 
  
  
Loperamide 
 
9.94 7.77 
 
 9.3 
  
Loratadine 
 
 1.9 
 
 1.9 
  
Mannitol 
 
0.88 0.82 
 
  
  
Maprotiline 
 
1.05  
 
  
  
Meprobamate 3.3 0.97  0.76  1.7 0.6380 
 
Metoclopramide 13.2   0.31  6.6 0.3650 
 
Midazolam 2.0 1.01 0.81 0.0272  1 0.0230 
 
Nelfinavir 
 
22.3 8.86 
 
  
  
Nortriptyline 
 
1.39  
 
 1.8 
  
Perphenazine 4.7 1.47  
 
  0.0040 
 
Phenytoin 2.8   0.081  1.2 0.0820 
 
Propranolol 
 
1.04 1.04 
 
  
  
Quinidine 
 
 27.2 0.037  i)   36 0.0392  j) 
 
Risperidone 20.8 1.61  0.067  10 0.0990 
 
 
 
Continued 
Drug 
MDR1-MDCKII Mouse Rat 
 
ER  fu,brain 
Kin 
(ml/100g/min) 
ER fu,brain 
Kin 
(ml/100g/min) 
(Ref) a) b) c) d) e) f) a) a) 
Ritonavir 
 
 54.4 
 
 1.2 
  
Ritzatriptan 8.4   0.348  i)   0.2930 
 
Saquinavir 
 
261 165 
 
  
  
Selegiline 0.8 0.76  0.056  1.1 0.0736 
 
Sertraline 2.6   0.0066 205 1.1 0.0009 403 
Sumatriptan 2.9 1.48 1.37 0.36  i)   0.7240 
 
Tacrine 1.1 0.93  
 
  0.1240 
 
Terfenadine 
 
2.88 4.66 
 
  
  
Trazodone 1.1 0.94  0.047  0.89 0.0550 
 
Venlafaxine 4.7   0.21  1.8 0.2160 
 
Verapamil 
 
1.73 1.16 
 
 17 
  
Vinblastine 
 
  
 
1.5  k)  
 
1.44  g) 
Zolpidem 
 
1.14  
 
 1.4 
  
 
References are reported for each column except for single values taken from separate 
publications, which are marked with letters corresponding to the references. 
a) Summerfield et al. 2007 
b) Mahar Doan et al. 2002 
c) Polli et al. 2001 
d) Maurer et al. 2005 
e) Dagenais et al. 2009 
f) Doran et al. 2005 
g) Cisternino et al. 2004 
h) Zhao et al. 2009 
i) Kalvass et al. 2007c 
j) Becker and Liu 2006 
k) Cisternino et al. 2004 
 
 
 
  
 
 
APPENDIX 4 
Results of Correlation Studies  
 
Lines represent the best fit of the linear regression. Trend line equations (y) and R2 
values (R2) are reported.  References for all data are found in Appendix 3. 
 
 
APPENDIX 5 
 
Model Structure Validation with Diazepam 
 
 
Plasma and brain unbound concentrations (dpm/ml *104) after continuous infusion of 
100 ?l/min for 60 min and then 16 ?l/min of 3.712*107 dpm/ml[N-methyl-3H]diazepam 
in rats predicted by the model (A) reported by Dubey et al. 1989 (B). The infusion 
scheme is shown below figure B. 
 
  
 
 
APPENDIX 6   
Simulation Results from the In Vitro Model.  
Results are reported here as an example for simulations where Km = 50 ?M and test 
concentration is 1 ?M. Vmax range 0.001-0.1 ?mol/min and Papp range 0.1-10 *10-6 cm/s. 
 
Vmax 
??mol/min) Km (?M) 
Vmax/Km 
(ml/min) 
Ppass 
(*10-6 cm/s) 
Papp Api-Baso 
(*10-6 cm/s) 
Papp  Baso-Api 
(*10-6 cm/s) ER 
0.001 50 0.02 0.10 0.100 0.397 3.98 
0.001 50 0.02 0.25 0.250 0.547 2.19 
0.001 50 0.02 0.50 0.498 0.795 1.60 
0.001 50 0.02 1.00 0.994 1.290 1.30 
0.001 50 0.02 2.50 2.466 2.759 1.12 
0.001 50 0.02 5.00 4.866 5.156 1.06 
0.001 50 0.02 10.00 9.476 9.758 1.03 
0.0025 50 0.05 0.10 0.100 0.843 8.44 
0.0025 50 0.05 0.25 0.249 0.992 3.98 
0.0025 50 0.05 0.50 0.498 1.239 2.49 
0.0025 50 0.05 1.00 0.994 1.733 1.74 
0.0025 50 0.05 2.50 2.464 3.198 1.30 
0.0025 50 0.05 5.00 4.863 5.587 1.15 
0.0025 50 0.05 10.00 9.471 10.175 1.07 
0.005 50 0.1 0.10 0.100 1.584 15.88 
0.005 50 0.1 0.25 0.249 1.732 6.95 
0.005 50 0.1 0.50 0.498 1.979 3.98 
0.005 50 0.1 1.00 0.993 2.470 2.49 
0.005 50 0.1 2.50 2.462 3.927 1.60 
0.005 50 0.1 5.00 4.858 6.304 1.30 
0.005 50 0.1 10.00 9.461 10.869 1.15 
0.0075 50 0.15 0.10 0.100 2.324 23.32 
0.0075 50 0.15 0.25 0.249 2.471 9.93 
0.0075 50 0.15 0.50 0.497 2.717 5.46 
0.0075 50 0.15 1.00 0.992 3.205 3.23 
0.0075 50 0.15 2.50 2.459 4.655 1.89 
0.0075 50 0.15 5.00 4.853 7.020 1.45 
0.0075 50 0.15 10.00 9.452 11.562 1.22 
0.01 50 0.2 0.10 0.100 3.062 30.76 
0.01 50 0.2 0.25 0.249 3.209 12.90 
0.01 50 0.2 0.50 0.497 3.453 6.95 
0.01 50 0.2 1.00 0.991 3.939 3.98 
0.01 50 0.2 2.50 2.457 5.382 2.19 
0.01 50 0.2 5.00 4.849 7.735 1.60 
0.01 50 0.2 10.00 9.443 12.253 1.30 
0.02 50 0.4 0.10 0.099 6.001 60.52 
0.02 50 0.4 0.25 0.248 6.145 24.81 
 
 
Continued 
Vmax 
??mol/min) Km (?M) 
Vmax/Km 
(ml/min) 
Ppass 
(*10-6 cm/s) 
Papp Api-Baso 
(*10-6 cm/s) 
Papp  Baso-Api 
(*10-6 cm/s) ER 
0.02 50 0.4 0.50 0.495 6.384 12.90 
0.02 50 0.4 1.00 0.987 6.860 6.95 
0.02 50 0.4 2.50 2.447 8.273 3.38 
0.02 50 0.4 5.00 4.829 10.579 2.19 
0.02 50 0.4 10.00 9.406 15.004 1.60 
0.04 50 0.8 0.10 0.098 11.808 120.05 
0.04 50 0.8 0.25 0.246 11.946 48.62 
0.04 50 0.8 0.50 0.491 12.175 24.81 
0.04 50 0.8 1.00 0.979 12.632 12.90 
0.04 50 0.8 2.50 2.428 13.988 5.76 
0.04 50 0.8 5.00 4.791 16.199 3.38 
0.04 50 0.8 10.00 9.332 20.441 2.19 
0.06 50 1.2 0.10 0.098 17.523 179.57 
0.06 50 1.2 0.25 0.244 17.655 72.43 
0.06 50 1.2 0.50 0.487 17.875 36.71 
0.06 50 1.2 1.00 0.971 18.313 18.86 
0.06 50 1.2 2.50 2.409 19.612 8.14 
0.06 50 1.2 5.00 4.754 21.730 4.57 
0.06 50 1.2 10.00 9.259 25.793 2.79 
0.08 50 1.6 0.10 0.097 23.147 239.09 
0.08 50 1.6 0.25 0.242 23.273 96.24 
0.08 50 1.6 0.50 0.483 23.484 48.62 
0.08 50 1.6 1.00 0.963 23.903 24.81 
0.08 50 1.6 2.50 2.390 25.147 10.52 
0.08 50 1.6 5.00 4.716 27.174 5.76 
0.08 50 1.6 10.00 9.187 31.060 3.38 
0.1 50 2 0.10 0.096 28.681 298.61 
0.1 50 2 0.25 0.240 28.802 120.05 
0.1 50 2 0.50 0.479 29.004 60.52 
0.1 50 2 1.00 0.956 29.405 30.76 
0.1 50 2 2.50 2.371 30.594 12.90 
0.1 50 2 5.00 4.679 32.531 6.95 
0.1 50 2 10.00 9.115 36.244 3.98 
 
